P.4.034 Neuropsychiatric symptoms in APOE genotyped Alzheimer's disease patients: Contributions to diagnosis and prognosis of the disease (English)
- New search for: Alvarez, A.
- New search for: Laredo, M.
- New search for: Couceiro, V.
- New search for: Fernandez-Novoa, L.
- New search for: Sampedro, C.
- New search for: Cacabelos, R.
- New search for: Vargas, M.
- New search for: Aleixandre, M.
- New search for: Alvarez, A.
- New search for: Laredo, M.
- New search for: Couceiro, V.
- New search for: Fernandez-Novoa, L.
- New search for: Sampedro, C.
- New search for: Cacabelos, R.
- New search for: Vargas, M.
- New search for: Aleixandre, M.
In:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
;
13
;
S399-S400
;
2003
-
ISSN:
- Article (Journal) / Print
-
Title:P.4.034 Neuropsychiatric symptoms in APOE genotyped Alzheimer's disease patients: Contributions to diagnosis and prognosis of the disease
-
Contributors:Alvarez, A. ( author ) / Laredo, M. ( author ) / Couceiro, V. ( author ) / Fernandez-Novoa, L. ( author ) / Sampedro, C. ( author ) / Cacabelos, R. ( author ) / Vargas, M. ( author ) / Aleixandre, M. ( author )
-
Published in:EUROPEAN NEUROPSYCHOPHARMACOLOGY ; 13 ; S399-S400
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam.
-
Publication date:2003-01-01
-
Size:S399-S400
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.8 / 615.1
- Further information on Dewey Decimal Classification
-
Classification:
-
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 13
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trialBrook, O. / van Hout, H. / Nieuwenhuyse, H. / Heerdink, E. et al. | 2003
- 11
-
Chronic citalopram treatment induces time-dependent changes in the expression and DNA-binding activity of transcription factor AP-2 in rat brainBerggard, C. / Damberg, M. / Oreland, L. et al. | 2003
- 19
-
Effects of partial locus coeruleus denervation and chronic mild stress on behaviour and monoamine neurochemistry in the ratHaidkind, R. / Eller, M. / Harro, M. / Kask, A. / Rinken, A. / Oreland, L. / Harro, J. et al. | 2003
- 29
-
Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levelsNechmad, A. / Maayan, R. / Ramadan, E. / Morad, O. / Poyurovsky, M. / Weizman, A. et al. | 2003
- 33
-
The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidolProcyshyn, R. M. / Tsai, G. / Wasan, K. M. et al. | 2003
- 37
-
Issues in the treatment of bipolar disorderKasper, S. et al. | 2003
- 39
-
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic studyAlvarez, E. / Bobes, J. / Gomez, J. C. / Sacristan, J. A. / Canas, F. / Carrasco, J. L. / Gascon, J. / Gibert, J. / Gutierrez, M. et al. | 2003
- 43
-
Diagnostic issues in bipolar disorderAngst, J. / Gamma, A. / Benazzi, F. / Ajdacic, V. / Eich, D. / Rossler, W. et al. | 2003
- 49
-
Increased corneal temperature in drug-free male schizophrenia patientsShiloh, R. / Portuguese, S. / Bodinger, L. / Katz, N. / Sigler, M. / Hermesh, H. / Munitz, H. / Weizman, A. et al. | 2003
- 51
-
Latest maintenance data on lithium in bipolar disorderGoodwin, G. M. / Geddes, J. R. et al. | 2003
- 53
-
Influence of antidepressants on intracellular levels of cyclic adenosine monophosphate in human peripheral blood mononuclear cellsKenis, G. / Steinbusch, H. / De Baets, M. / Maes, M. et al. | 2003
- 57
-
Latest maintenance data on lamotrigine in bipolar disorderCalabrese, J. R. / Vieta, E. / Shelton, M. D. et al. | 2003
- 57
-
The pharmacology of putative early-onset antidepressant strategiesBlier, P. et al. | 2003
- 67
-
Chairmen's IntroductionRoose, S. P. / Pinder, R. M. et al. | 2003
- 67
-
Serum iron levels in schizophrenic patients with or without akathisiaKuloglu, M. / Atmaca, M. / Ustundag, B. / Canatan, H. / Gecici, O. / Tezcan, E. et al. | 2003
- 69
-
Risk factors and predictors of compliance in depressionDemyttenaere, K. et al. | 2003
- 73
-
Milnacipran in the treatment of bulimia nervosa: a report of 16 casesEl-Giamal, N. / de Zwaan, M. / Bailer, U. / Strnad, A. / Schussler, P. / Kasper, S. et al. | 2003
- 77
-
Benefits of different drug formulations in psychopharmacologyFrijlink, H. W. et al. | 2003
- 81
-
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trialCavazzoni, P. / Tanaka, Y. / Roychowdhury, S. M. / Breier, A. / Allison, D. B. et al. | 2003
- 85
-
Compliance: the impact of adverse events and tolerability on the physician's treatment decisionsRoose, S. P. et al. | 2003
- 87
-
Alternation learning in OCD/schizophrenia patientsHermesh, H. / Weizman, A. / Gur, S. / Zalsman, G. / Shiloh, R. / Zohar, J. / Gross-Isseroff, R. et al. | 2003
- 93
-
Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorderHemmings, S. M. / Kinnear, C. J. / Niehaus, D. J. / Moolman-Smook, J. C. / Lochner, C. / Knowles, J. A. / Corfield, V. A. / Stein, D. J. et al. | 2003
- 99
-
Polyunsaturated fatty acid deficit in patients with bipolar maniaChiu, C. C. / Huang, S. Y. / Su, K. P. / Lu, M. L. / Huang, M. C. / Chen, C. C. / Shen, W. W. et al. | 2003
- 105
-
CSF testosterone in 43 male suicide attemptersGustavsson, G. / Traskman-Bendz, L. / Higley, J. D. / Westrin, A. et al. | 2003
- 111
-
Effects of zolpidem 10 mg, zopiclone 7.5 mg and flunitrazepam 1 mg on night-time motor activityDenise, P. / Bocca, M. L. et al. | 2003
- 117
-
SSRIs antidepressant activity is influenced by Gb3 variantsSerretti, A. / Lorenzi, C. / Cusin, C. / Zanardi, R. / Lattuada, E. / Rossini, D. / Lilli, R. / Pirovano, A. / Catalano, M. / Smeraldi, E. et al. | 2003
- 123
-
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled studyPoyurovsky, M. / Koren, D. / Gonopolsky, I. / Schneidman, M. / Fuchs, C. / Weizman, A. / Weizman, R. et al. | 2003
- 129
-
Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorderWinkler, D. / Willeit, M. / Wolf, R. / Stamenkovic, M. / Tauscher, J. / Pjrek, E. / Konstantinidis, A. / Schindler, S. / Barnas, C. / Kasper, S. et al. | 2003
- 135
-
Manic symptoms associated with quetiapine treatmentLykouras, L. / Oulis, P. / Hatzimanolis, J. et al. | 2003
- 137
-
Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviourLeppamaki, S. / Partonen, T. / Vakkuri, O. / Lonnqvist, J. / Partinen, M. / Laudon, M. et al. | 2003
- 147
-
Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neurolepticsIlli, A. / Kampman, O. / Anttila, S. / Roivas, M. / Mattila, K. M. / Lehtimaki, T. / Leinonen, E. et al. | 2003
- 153
-
5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placeboBroocks, A. / Meyer, T. / Opitz, M. / Bartmann, U. / Hillmer-Vogel, U. / George, A. / Pekrun, G. / Wedekind, D. / Ruther, E. / Bandelow, B. et al. | 2003
- 165
-
Adenosine receptor agonists or antagonists alter antinociception, but did not show an interaction with imipramine-induced antinociception in the formalin test in miceZarrindast, M. R. / Matinrokh, H. / Mojtahedzadeh-Ardebili, P. et al. | 2003
- 173
-
Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellumLicht, R. W. / Larsen, J. O. / Smith, D. / Braendgaard, H. et al. | 2003
- 177
-
Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in ratsAhlqvist, J. / Isacson, R. / Wahlestedt, C. / Salmi, P. et al. | 2003
- 183
-
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic studyZalsman, G. / Frisch, A. / Lev-Ran, S. / Martin, A. / Michaelovsky, E. / Bensason, D. / Gothelf, D. / Nahshoni, E. / Tyano, S. / Weizman, A. et al. | 2003
- 187
-
Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophreniaDaenen, E. W. / Wolterink, G. / Van Der Heyden, J. A. / Kruse, C. G. / Van Ree, J. M. et al. | 2003
- 199
-
Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brainO'Donnell, T. / Rotzinger, S. / Nakashima, T. T. / Hanstock, C. C. / Ulrich, M. / Silverstone, P. H. et al. | 2003
- 209
-
Effects of 8-OH-DPAT on open field performance of young and aged rats prenatally exposed to diazepam: a tool to reveal 5-HT1A receptor functionCannizzaro, C. / Martire, M. / Cannizzaro, E. / Monastero, R. / Gagliano, M. / Mineo, A. / Provenzano, G. et al. | 2003
- 219
-
Publisher`s Note| 2003
- 220
-
Effects of chronic lithium and sodium valproate on concentrations of brain amino acidsO'Donnell, T. / Rotzinger, S. / Ulrich, M. / Hanstock, C. C. / Nakashima, T. T. / Silverstone, P. H. et al. | 2003
- 228
-
Distribution of 5-HT4 receptors in the postmortem human brain-an autoradiographic study using [125I]SB 207710Varnas, K. / Halldin, C. / Pike, V. W. / Hall, H. et al. | 2003
- 235
-
S100B and response to treatment in major depression: a pilot studyArolt, V. / Peters, M. / Erfurth, A. / Wiesmann, M. / Missler, U. / Rudolf, S. / Kirchner, H. / Rothermundt, M. et al. | 2003
- 241
-
Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in ratsSharma, M. / Gupta, Y. K. et al. | 2003
- 249
-
Attenuated stress responsiveness in an animal model for neurodevelopmental psychopathological disordersTerpstra, J. / Gispen-De Wied, C. C. / Broekhoven, M. H. / Frankhuijzen, A. C. / Kahn, R. S. / van Ree, J. M. / Wiegant, V. M. et al. | 2003
- 257
-
Influence of sex hormone antagonists on the anticonvulsant action of conventional antiepileptic drugs against amygdala-kindled seizures in male and female ratsBorowicz, K. K. / Kleinrok, Z. / Czuczwar, S. J. et al. | 2003
- 267
-
Omega-3 fatty acids in major depressive disorderSu, K. P. / Huang, S. Y. / Chiu, C. C. / Shen, W. W. et al. | 2003
- 273
-
Hyperresponsiveness to phencyclidine in animals lesioned in the amygdala on day 7 of lifeDaenen, E. W. / Wolterink, G. / Van Ree, J. M. et al. | 2003
- 281
-
Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on immobilization stress-induced antinociception in the mouseChung, K. M. / Choi, S. S. / Choi, M. R. / Suh, H. W. et al. | 2003
- 289
-
Sensitised locomotion does not predict conditioned locomotion in cocaine-treated mice: further evidence against the excitatory conditioning model of context-dependent sensitisationTirelli, E. / Tambour, S. / Michel, A. et al. | 2003
- 297
-
Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological interventionBuitelaar, J. K. / Montgomery, S. A. / van Zwieten-Boot, B. J. et al. | 2003
- 305
-
Conduct disorder: guidelines for investigating efficacy of pharmacological interventionBuitelaar, J. K. / Montgomery, S. A. / van Zwieten-Boot, B. J. et al. | 2003
- 313
-
D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorderLawford, B. R. / McD. Young,, R. / Noble, E. P. / Kann, B. / Arnold, L. / Rowell, J. / Ritchie, T. L. et al. | 2003
- 321
-
Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levelsShah, Z. A. / Sharma, P. / Vohora, S. B. et al. | 2003
- 327
-
Brain neurosteroid changes after paroxetine administration in miceNechmad, A. / Maayan, R. / Spivak, B. / Ramadan, E. / Poyurovsky, M. / Weizman, A. et al. | 2003
- 333
-
CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotypeNordin, C. / Dahl, M. L. / Eklundh, T. / Eriksson, M. / Sjoberg, S. et al. | 2003
- 337
-
Effects of serotonin 5-HT1/2 receptor agonists in a limited-access operant food intake paradigm in the ratDe Vry, J. / Schreiber, R. / Daschke, A. / Jentzsch, K. R. et al. | 2003
- 347
-
Effects of coaching by community pharmacists on psychological symptoms of antidepressant users; a randomised controlled trialBrook, O. H. / Van Hout, H. P. / Nieuwenhuysea, H. / De Haan, M. et al. | 2003
- 355
-
Antinociceptive effects of tricyclic antidepressants and their noradrenergic metabolitesRojas-Corrales, M. O. / Casas, J. / Moreno-Brea, M. R. / Gibert-Rahola, J. / Mico, J. A. et al. | 2003
- 365
-
Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European studyOswald, P. / Souery, D. / Massat, I. / Del-Favero, J. / Linotte, S. / Papadimitriou, G. / Dikeos, D. / Kaneva, R. / Milanova, V. / Oruc, L. et al. | 2003
- 369
-
Behavioural changes after different stress paradigms: prepulse inhibition increased after physical, but not emotional stressPijlman, F. T. / Herremans, A. H. / van de Kieft, J. / Kruse, C. G. / van Ree, J. M. et al. | 2003
- 381
-
Toxic rise of clozapine plasma concentrations in relation to inflammationHaack, M. J. / Bak, M. L. / Beurskens, R. / Maes, M. / Stolk, L. M. / Delespaul, P. A. et al. | 2003
- 387
-
Autoradiographic imaging of the serotonin transporter in the brain of rats and pigs using S-([18F]fluoromethyl)-(+)-McN5652Kretzschmar, M. / Brust, P. / Zessin, J. / Cumming, P. / Bergmann, R. / Johannsen, B. et al. | 2003
- 399
-
Corrigendum to "Effects of 8-OH-DPAT on open field performance of young and aged rats prenatally exposed to diazepam: a tool to reveal 5-HT1A receptor function"Cannizzaro, C. / Martire, M. / Provenzano, G. / Monastero, R. / Gagliano, M. / Plescia, F. / Mineo, A. / Cannizzaro, E. et al. | 2003
- 401
-
Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responsesMaldonado, R. / Valverde, O. et al. | 2003
- 411
-
Molecular mechanisms of tolerance to and withdrawal of GABAA receptor modulatorsBiggio, G. / Dazzi, L. / Biggio, F. / Mancuso, L. / Talani, G. / Busonero, F. / Mostallino, M. C. / Sanna, E. / Follesa, P. et al. | 2003
- 424
-
Drug dependence and the endogenous opioid systemGerrits, M. A. / Lesscher, H. B. / van Ree, J. M. et al. | 2003
- 435
-
The impact of stress on addictionE. Goeders, N. et al. | 2003
- 442
-
Neuroadaptive mechanisms of addiction: studies on the extended amygdalaKoob, G. F. et al. | 2003
- 453
-
Brain imaging studies in human addictsDaglish, M. R. / Nutt, D. J. et al. | 2003
- 459
-
Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohortAbi-Dargham, A. / Kegeles, L. S. / Martinez, D. / Innis, R. B. / Laruelle, M. et al. | 2003
- 469
-
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessmentMason, B. J. et al. | 2003
- 476
-
Pharmacological treatments for heroin and cocaine addictionvan den Brink, W. / van Ree, J. M. et al. | 2003
- 488
-
Author Index (Volume 13)| 2003
- 492
-
Key Word Index (Volume 13)| 2003
- 500
-
Contents of Volume 13 (2003)| 2003
- S1
-
Study of the neurobiological mechanisms of cannabinoid dependence by using knockout miceMaldonado, R. et al. | 2003
- S4
-
Endogenous opioids and drug dependenceGerrits, M. A. / van Ree, J. M. et al. | 2003
- S6
-
Sensitization and addictionRobinson, T. E. et al. | 2003
- S9
-
Child psychopathology, biological risk factors and addictionHill, S. Y. et al. | 2003
- S11
-
Conditioning, drug-seeking and its neural basisEveritt, B. J. et al. | 2003
- S12
-
Advanced treatment of alcohol and nicotine addictionMason, B. et al. | 2003
- S13
-
Treatment options for heroin and cocaine addictionvan den Brink, W. / van Ree, J. M. et al. | 2003
- S17
-
Theoretical and experimental basis for using cholecystokinin analogues in the treatment of alcohol and drug addictionsProskuryakova, T. V. / Anokhina, I. P. et al. | 2003
- S18
-
In vivo evidence that central nitrogen monoxide is activated by amphetamine: Is this system implicated in the neurotoxicity of drugs of abuse?Crespi, F. / Lacroix, L. P. / Bianchi, M. / Heidbreder, C. A. et al. | 2003
- S19
-
The GABAA receptor agonist muscimol modulates the locomotor, sensitizing and discriminative stimulus effects of cocaine in ratsFilip, M. / Jungersmith, K. / Papla, I. / Nowak, E. / Przegalinski, E. et al. | 2003
- S20
-
CART peptides in drug abuse and dependenceHunter, R. G. / Jaworski, J. N. / Dominguez, G. / Kuhar, M. J. et al. | 2003
- S21
-
The selective dopamine D3 receptor antagonist SB-277011 enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortexLacroix, L. P. / Hows, M. E. / Shah, A. J. / Hagan, J. J. / Heidbreder, C. A. et al. | 2003
- S22
-
Behavioral effects of cocaine and quantitative dopamine receptor autoradiography in MOR-1 knockout mice and chronic naltrexone treated miceLesscher, H. M. / Bossong, M. / Hordijk, H. / van der Linden, A. J. / Spruijt, B. M. / Bailey, A. / Kitchen, I. / Burbach, J. P. / van Ree, J. M. / Gerrits, M. A. et al. | 2003
- S23
-
Present psychopharmacological prospects for the treatment of amphetamine abstinence syndrome in persons with suicidal riskMarinescu, D. / Udristoiu, T. / Chirita, A. et al. | 2003
- S24
-
Effect of repetitive administration of morphine on G alpha(q), G alpha(11) and G alpha(12) genes' expression in the rat prefrontal cortexNalepa, I. / Zelek-Molik, A. / Bielawski, A. / Vetulani, J. et al. | 2003
- S25
-
Effects of baclofen, a GABAB receptor agonist, on the cocaine-evoked locomotor, sensitizing and discriminative stimulus effects in ratsPapla, I. / Jungersmith, K. / Filip, M. / Czepiel, K. / Przegalinski, E. et al. | 2003
- S26
-
Effect of the mGluR5 receptor antagonist MPEP on cocaine, nicotine and food-seeking behaviourPilla, M. / Tessari, M. / Heidbreder, C. A. et al. | 2003
- S27
-
Efficacy of reboxetine treatment for cocaine dependenceSzerman, N. / Peris, L. / Mesias, B. / Colis, P. / Rosa, J. J. / Prieto, A. et al. | 2003
- S28
-
Measurement of the personality characteristics of ecstasy users by the Cloninger's temperament and character inventoryTorrens, M. / Gines, J. M. / Martin-Santos, R. / Gutierrez, F. / Poudevida, S. / Farre, M. / de la Torre, R. et al. | 2003
- S29
-
Modification of morphine analgesia, tolerance and abstinence by 1,2,3,4-tetrahydroisoquinolineVetulani, J. / Antkiewicz-Michaluk, L. / Michaluk, J. et al. | 2003
- S31
-
Dopamine response to drugs of abuse in the nucleus accumbens of the mouse: A shell-core investigationZocchi, A. / Varnier, G. / Sartori, I. / Girlanda, E. / Zanetti, L. / Heidbreder, C. A. et al. | 2003
- S93
-
L.01 Novel strategies for treatment of schizophrenia and Parkinson's disease. Focus on receptor-receptor interactions in the basal gangliaFuxe, K. / Ferre, S. / Woods, A. / Lluis, C. / Franco, R. / Agnati, L. et al. | 2003
- S95
-
S.01.02 Efficacy of partial dopamine agonistsMoller, H. J. et al. | 2003
- S96
-
S.02.01 Psychological and pharmacological therapies in combination in depressionPaykel, E. et al. | 2003
- S97
-
S.02.04 The impact of depression on the outcome of physical diseasesBisserbe, J. C. / Flament, M. / Paterniti, S. et al. | 2003
- S98
-
S.02.05 The pathophysiology of pain in depressionMico, J. A. / Rojas-Corrales, M. O. / Berrocoso, E. / Elorza, J. et al. | 2003
- S99
-
S.03.01 In vivo and in vitro models of AD demonstrate a role of distinct phosphorylation sites of tau in neurofibrillary tangle formationChen, F. / Schild, A. / Kurosinski, P. / Pennanen, L. / Hoerndli, F. / David, D. / Ferrari, A. / Nitsch, R. M. / Gotz, J. et al. | 2003
- S102
-
S.04.02 Biochemical modulation of AMPA receptor function by antidepressantsSvenningsson, P. / Tzavara, E. / Nomikos, G. / McEwen, B. / Greengard, P. et al. | 2003
- S103
-
S.04.05 NMDA receptor blockade increases glutamate efflux in the medial prefrontal cortex: Role of 5-HT2A receptorsCeglia, I. / Carli, M. / Invernizzi, R. W. et al. | 2003
- S104
-
S.04.07 Role of monoamine oxidase in imidazoline2 binding site mediated function in rat brainPaterson, L. / Tyacke, R. J. / Robinson, E. S. / Nutt, D. J. / Hudson, A. L. et al. | 2003
- S105
-
S.05.01 Is bipolar depression a different indication? A European regulatory point of viewBroich, K. et al. | 2003
- S106
-
S.05.02 Anticonvulsant prophylaxis in bipolar disorder: Is phenytoin the prototype?Belmaker, R. H. / Mishory, A. / Bersudsky, Y. et al. | 2003
- S107
-
S.05.04 Inhibition of myo-inositol-phosphate synthase by valproate; a mechanism for mood stabilization?Greenberg, M. L. / Ding, D. / Shaltiel, G. / Ju, S. / Agam, G. / Belmaker, R. H. et al. | 2003
- S108
-
S.05.05 Chronobiological treatment of bipolar depressionBenedetti, F. / Colombo, C. / Pontiggia, A. / Bernasconi, A. / Barbini, B. / Smeraldi, E. et al. | 2003
- S109
-
S.06.03 Is dopamine a variable in PET-studies on drug induced receptor occupancy?Farde, L. et al. | 2003
- S110
-
S.07.01 Functional genomics of schizophrenia: Alterations of specific pathwaysMirnics, K. et al. | 2003
- S113
-
S.08.03 mGluR subtypes in neuronal circuits of the primate and rodent brain: Potential morphological substrate for psychiatric disordersMrzljak, L. et al. | 2003
- S114
-
S.08.04 Allosteric modulators of mGluRGasparini, F. et al. | 2003
- S115
-
S.09.01 Immunization therapy for Alzheimer's diseaseHock, C. / Nitsch, R. M. et al. | 2003
- S116
-
S.09.04 Memantine: Treatment opportunity for severe dementiaJelic, V. / Winblad, B. et al. | 2003
- S119
-
S.10.01 Animal models for eating disordersAdan, R. A. / Hillebrand, J. / Van Elburg, A. / Koeners, M. / Van Engeland, H. / Kas, M. J. et al. | 2003
- S120
-
S.10.02 Psychoneuroendocrinological aspects of anorexia nervosaVan Engeland, H. / Van Elburg, A. / Kas, M. / Adan, R. A. et al. | 2003
- S121
-
S.10.05 Role of 5HT in eating disordersKaye, W. / Frank, G. / Barbarich, N. / Henry, S. / Bailer, U. et al. | 2003
- S122
-
S.11.01 The amygdala and dopamineGrace, A. / Rosenkranz, A. et al. | 2003
- S123
-
S.11.02 The amygdala and social cognitionAleman, A. et al. | 2003
- S124
-
S.11.03 Fear, amygdala and the X chromosomeMorris, J. / Skuse, D. H. / Dolan, R. J. et al. | 2003
- S125
-
S.11.04 The amygdala and mood disordersPhillips, M. / Lawrence, N. / Surguladze, S. / Kerr, N. / Williams, A. et al. | 2003
- S127
-
S.12.02 Nicotinic receptor pathologies in human brainPerry, E. et al. | 2003
- S128
-
S.12.04 a7 Nicotinic acetylcholine receptors: Neuropsychopharmacological significanceSvensson, T. H. et al. | 2003
- S129
-
S.12.05 Treating the cognitive symptoms of Alzheimer's disease with nicotinic a-7 receptor agonistsCross, A. J. et al. | 2003
- S130
-
S.13.01 CRF1 antagonists for anxietyZorrilla, E. / Fekete, E. / Mason, B. J. / Wirsching, P. / Janda, K. D. / Koob, G. F. et al. | 2003
- S131
-
S.13.02 Anxiolytic-like effects of substance P (NK1 receptor) antagonists (SPAs) in preclinical assaysRupniak, N. et al. | 2003
- S132
-
S.13.04 Pregabalin: A mechanistically and therapeutically novel anxiolyticPande, A. et al. | 2003
- S133
-
S.14.04 Progression in braim abnormalities and illness severity in schizophreniaMathalon, D. H. / Sullivan, E. V. / Lim, K. O. / Pfefferbaum, A. et al. | 2003
- S134
-
S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophreniaSharma, T. / Lieberman, J. A. / McEvoy, J. P. / Perkins, D. O. / Hamer, R. M. / Zipursky, R. B. / Kahn, R. S. / Gur, R. E. / Centorrino, F. / Glick, I. et al. | 2003
- S135
-
S.15.03 Serotoninergic receptor subtypes in cognitionBuhot, M. C. / Wolff, M. / Segu, L. et al. | 2003
- S136
-
S.15.04 Role of central CRF and NPY receptors in the autonomic expression of conditioned fearStiedl, O. / Meyer, M. et al. | 2003
- S137
-
S.15.05 Hippocampal neuropeptides in learning and memory: Implications for cognitive dysfunction and agingOgren, S. O. / Kuzmin, A. / Kehr, J. / Terenius, L. / Sandin, J. et al. | 2003
- S138
-
S.16.01 Hypocretins and histamine in the physiology and pathology of vigilance statesPretl, M. / Nishino, S. / Mignot, E. et al. | 2003
- S139
-
S.16.02 Histamine and orexin neurons: Synergistic and complementary regulation on the sleep-wake cycle?Lin, J. S. et al. | 2003
- S140
-
S.16.03 Histaminergic neurons, attention and learningBlandina, P. / Passani, M. B. et al. | 2003
- S143
-
S.17.04 Physical treatment of refractory depression in old ageKatona, C. et al. | 2003
- S144
-
S.17.05 Treatment of depression in the cognitively impaired elderlyKarlsson, I. et al. | 2003
- S145
-
S.18.04 Drug discovery for anxiety disordersGorman, J. et al. | 2003
- S146
-
S.19.02 IGF-1 signaling: Role in neuroprotection and major depressionTorres-Aleman, I. / Trejo, J. L. / Garcia-Galloway, E. / Carro, E. et al. | 2003
- S147
-
S.19.03 Trophic factors - role in depressive illnessVaidya, V. et al. | 2003
- S148
-
S.19.05 Perspective role of stem cells application in neuropsychiatric researchSykova, E. et al. | 2003
- S149
-
S.20.02 Effects of psychostimulants in the absence of dopamine transporterGiros, B. / Morice, E. / Nosten-Bertrand, M. et al. | 2003
- S151
-
S.20.01 Adrenal & CSF neurosteroids as mediators of HPA axis upregulation and symptom production in premenopausal women with PTSDRasmusson, A. / Guidotti, A. / Charney, D. / Vojvoda, D. / Lipschitz, D. / Weisman, D. / Krystal, J. et al. | 2003
- S152
-
S.21.03 Developing an animal model for post-traumatic stress disorderYadid, G. / Gispan-Herman, I. / Kesner, Y. / Weizman, Y. / Mendelman, A. / Zohar, J. et al. | 2003
- S153
-
S.21.05 Ten myths of PTSDZohar, J. et al. | 2003
- S155
-
S.22.05 The neurobiology of pleiotropic traits in schizophreniaHolzman, P. S. / Matthysse, S. / Levy, D. L. et al. | 2003
- S157
-
S.23.03 Stress-induced anhedonia in rats: A validated simulation of depressionMoreau, J. L. et al. | 2003
- S158
-
S.23.05 Modeling schizophrenia in animalsLipska, B. et al. | 2003
- S159
-
S.24.02 Inverse agonism at dopamine receptorsStrange, P. et al. | 2003
- S160
-
S.24.03 Agonist trafficking of receptor stimulus and mRNA editing at serotonin2C receptorsClarke, W. / Berg, K. A. et al. | 2003
- S161
-
S.24.05 Agonist-antagonist binding: Relevance for therapeutic actionHoyer, D. et al. | 2003
- S163
-
S.25.03 Reducing risk of suicide in schizophreniaMeltzer, H. Y. et al. | 2003
- S164
-
S.25.04 Non-pharmacological prevention of suicidal behaviourRihmer, Z. et al. | 2003
- S165
-
S.26.03 Schizophrenia genes identified by positional cloning affect the glutamatergic systemStefansson, H. / Sigurdsson, E. / Steinthorsdottir, V. / Gulcher, J. R. / Petursson, H. / Stefansson, K. et al. | 2003
- S166
-
S.27.01 The dopamine D3 receptor as a therapeutic targetSchwartz, J. C. et al. | 2003
- S167
-
S.27.02 A partial D3 receptor agonist in schizophreniaLecrubier, Y. et al. | 2003
- S168
-
S.27.03 The D3 receptor gene and the pharmacogenetics of tardive dyskinesiaLerer, B. et al. | 2003
- S169
-
S.27.04 Dopamine D3 receptor in Parkinson's disease and schizophreniaJoyce, J. et al. | 2003
- S171
-
S.28.01 5-HT approaches to anxiety: Making sense of animal studiesMitchell, P. J. et al. | 2003
- S172
-
S.28.03 Facilitation of fear extinction by NMDA agonistsDavis, M. et al. | 2003
- S176
-
P.1.004 Repetitive transcranial magnetic stimulation (rTMS) as an add-on therapy in depression: A prospective, monocenter, randomized, double-blind, sham controlled trialWalpoth, M. / Hausmann, A. / Mechtecheriakov, S. / Kramer-Reinstadler, K. / Lechner, T. / Walch, T. / Deisenhammer, E. / Kemmler, G. / Rupp, C. / Kofler, M. et al. | 2003
- S177
-
P.1.007 A prospective trial of adjunctive short-term hormone replacement therapy to antidepressant treatment in postmenopausal women with depressionJoe, S. H. / Kim, J. W. / Kim, S. H. / Jung, I. G. / Lee, H. S. et al. | 2003
- S178
-
P.1.009 Temperamental mood lability and depressive mixed statesBenazzi, F. et al. | 2003
- S179
-
P.1.011 Meta-analysis of efficacy of two pilot clinical studies with a novel pentapeptide antidepressant, nemifitide, in the treatment of depressionMontgomery, S. A. / Feighner, J. P. / Sverdlov, L. / Abajian, H. / Hlavka, J. / Nicolau, G. / Freed, J. et al. | 2003
- S180
-
P.1.013 Serum thyroid-stimulating-hormone (TSH) in major depression: Relevance of "high normal" concentrationsCorruble, E. / Berlin, I. / Lemine, A. / Hardy, P. et al. | 2003
- S181
-
P.1.016 In vivo pharmacology of AZD1134, a novel 5-HT1B antagonistHudzik, T. / Smolka, J. / Litwin, L. / Porrey, T. / Pierson, E. et al. | 2003
- S182
-
P.1.018 Cross-sectional assessment of psychiatric morbidity, satisfaction with life and perceived social support in renal transplantation patients in Turkiye; a preliminary studySoykan, A. / Arapaslan, B. / Kumbasar, H. et al. | 2003
- S183
-
P.1.021 The effects of venlafaxine on behavioural effects in chronically stressed ratsNowakowska, E. / Kus, K. / Bobkiewicz-Kozlowska, T. et al. | 2003
- S185
-
P.1.026 Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and healthy controlsThierry, N. / Willeit, M. / Praschak-Rieder, N. / Zill, P. / Hornik, K. / Neumeister, A. / Hilger, E. / Kasper, S. et al. | 2003
- S187
-
P.1.031 Gepirone extended release (ER) in patients with anxious depressionFava, M. / Alpert, J. / Kremer, C. et al. | 2003
- S188
-
P.1.034 Chronic gepirone treatment alters regional 5-HT1A receptor coupling efficiency in rat brainWard, N. / Wren, P. / Henry, B. / McElroy, S. / Walker, G. / Epemolu, O. / Van Kalkeren, J. / Hill, D. R. et al. | 2003
- S190
-
P.1.039 Depression in the elderly: A comparative and correlational studyMatos-Pires, A. / Fernandes, L. / Pires-Barreira, D. / Borges, G. / Cavaglia, F. et al. | 2003
- S191
-
P.1.041 Growth hormone response to L-DOPA and dexamethasone suppression tests before and after treatment in depressive patientsEsel, E. / Kartalci, S. / Kula, M. / Turan, M. T. / Hacimusalar, Y. / Tutus, A. / Sofuoglu, S. et al. | 2003
- S192
-
P.1.043 Lithium induced alterations in NTP levels in human brain: A proton decoupled 31P MRS studyYildiz, A. / Sachs, G. S. / Tunca, Z. / Demopulos, C. M. / Moore, C. M. / Renshaw, P. F. et al. | 2003
- S193
-
P.1.045 Interactions between dopaminergic system and HPT axis in depression: Implication for pathogenesis of suicidal behaviorDuval, F. / Mokrani, M. C. / Monreal, J. / Hamel, B. / Fattah, S. / Macher, J. P. et al. | 2003
- S194
-
P.1.048 Metabolism phenotype and in vitro drug-drug interaction studies with nemifitide, a novel pentapeptide antidepressantNicolau, G. / Feighner, J. P. / Silber, P. / Chen, G. / Abajian, H. / Bathala, M. et al. | 2003
- S195
-
P.1.050 Subthreshold symptomatology and quality of life in a non psychiatric population: Usefulness of pharmacological treatmentMartinucci, M. / Goracci, A. / Scalcione, U. / Castrogiovanni, P. et al. | 2003
- S196
-
P.1.052 Lithium-induced psoriasis in bipolar disorder: Importance of common predisposing factors between effective symptomatology and psoriasisMartinucci, M. / Boccadamo, A. / Di Rienzo, M. / Sbaragli, C. et al. | 2003
- S197
-
P.1.054 Effect of combined administration of 5-HT1A or 5-HT1B receptor antagonists and antidepressant drugs in the forced swimming test in ratsTatarczynska, E. / Kldzinska, A. / Stachowicz, K. / Chojnacka-Wojcik, E. et al. | 2003
- S198
-
P.1.056 Canadian network for bipolar disorder (CAN-BD): Preliminary report of data on the first 126 patientsYatham, L. N. / Silverstone, P. / Gorman, C. / Baruch, P. / Leblanc, J. / Cervantes, P. / Beaulieu, S. et al. | 2003
- S199
-
P.1.059 EPID - the first epidemiological study on depression in Slovakia pharmacotherapy in depressive patientsNovotny, V. / Pecenak, J. / Heretik Sr, A. / Heretik Jr, A. / Ritomsky, A. et al. | 2003
- S200
-
P.1.061 Characteristics of attenders and non-attenders at a bipolar disorder psycho-education programmeEven, C. / Richard, H. / Kalck-Stern, M. / Friedman, S. / Guelfi, J. D. et al. | 2003
- S201
-
P.1.063 Effect of sub-chronic treatment with jarsin (extract of St John's wort) at two doses on evening salivary cortisol and melatonin in healthy male volunteersFranklin, M. / Reed, A. / Murck, H. et al. | 2003
- S202
-
P.1.065 Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of painOrtega-Alvaro, A. / Acebes, I. / Saracibar, G. / Echevarria, E. / Casis, L. / Mico, J. A. et al. | 2003
- S204
-
P.1.071 R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress modelPapp, M. / Gruca, P. / Bien, E. / Sanchez, C. et al. | 2003
- S205
-
P.1.073 R-citalopram functionally antagonizes escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporterStorustovui, S. / Sanchez, C. / Porzgen, P. / Brennum, L. T. / Larsen, A. K. / Pulis, M. / Ebert, B. et al. | 2003
- S207
-
P.1.078 Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depressionVieta, E. / Tohen, M. / Ketter, T. / Calabrese, J. / Andersen, S. / Detke, H. / Risser, R. / Corya, S. et al. | 2003
- S209
-
P.1.083 Efficacy of citalopram treatment in subjects with burning mouth syndrome with and without depressive disordersMiller, A. / Rabe-Jablonska, J. et al. | 2003
- S211
-
P.1.088 Interactions between SSRI and flattened glucocorticoid rhythm with respect to 5-HT function: Implications for antidepressant efficacyGartside, S. E. / Leitch, M. M. / Young, A. H. et al. | 2003
- S212
-
P.1.091 Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trialTohen, M. / Bowden, C. / Calabrese, J. / Chou, J. / Jacobs, T. / Baker, R. / Williamson, D. / Evans, A. et al. | 2003
- S213
-
P.1.093 The multi-central clinical study on the efficacy of paroxetine over anxiety symptoms in mixed anxiety-depressionKocabasoglu, N. / Corapcioglu, A. / Yargic, I. et al. | 2003
- S215
-
P.1.098 The S-enantiomer of citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitorsWiborg, O. / Chen, F. / Larsen, M. B. / Sanchez, C. et al. | 2003
- S217
-
P.1.103 Membrane lipids and serotonin uptake after long-term administration of antidepressantsFisar, Z. / Anders, M. / Tvrzicka, E. / Fuksova, K. et al. | 2003
- S218
-
P.1.105 Effects of electroconvulsive therapy on thyroid stimulating hormone response to thyrotropin-releasing hormone in depressive patientsTuran, T. / Kylyc, C. / Esel, E. / Kula, M. / Keles, S. / Basturk, M. et al. | 2003
- S219
-
P.1.107 Depression and painful physical symptoms in EuropePeveler, R. / Garcia-Cebrian, A. / Lothgren, A. / Ghandi, P. et al. | 2003
- S220
-
P.1.109 The effects of early maternal separation on pre- and post-synaptic 5-HT1A receptor binding in the rat brainTroakes, C. / Gartside, S. E. et al. | 2003
- S221
-
P.1.111 A steady-state evaluation of the effect of rifampicin on the pharmacokinetics of gepirone ER and metabolitesLam, Y. W. / Ereshefsky, L. / Port, A. / Timmer, C. J. / Dogterom, P. et al. | 2003
- S222
-
P.1.114 Effects of sertraline and venlafaxine on serum TNF-a in major depressive disorderTuglu, C. / Kara, H. / Caliyurt, O. / Vardar, E. / Abay, E. et al. | 2003
- S223
-
P.1.116 Phase-response effects of lormetazepam in depressive insomniaPontiggia, A. / Benedetti, F. / Smeraldi, E. / Bernasconi, A. / Florita, M. / Colombo, C. / Cropanese, I. et al. | 2003
- S224
-
P.1.118 Changes in depressive neuropsychological functioning during antidepressant treatmentFlorita, M. / Benedetti, F. / Colombo, C. / Bernasconi, A. / Pontiggia, A. / Cigala Fulgosi, M. / Barbini, B. / Smeraldi, E. et al. | 2003
- S225
-
P.1.121 Rapid assessment of cognitive distorsions in major depressionCigala Fulgosi, M. / Benedetti, F. / Florita, M. / Colombo, C. / Barbini, B. / Smeraldi, E. et al. | 2003
- S226
-
P.1.124 Milnacipran in the treatment of adolescent depression or dysthymiaTauscher-Wisniewski, S. / Friedrich, M. H. et al. | 2003
- S227
-
P.1.126 Effects of lamotrigine on neurocognitive measures in bipolar I patientsYatham, L. N. / Davis, K. H. / Khan, A. / Ginsberg, L. D. / Asnis, G. M. / Goodwin, F. K. et al. | 2003
- S228
-
P.1.129 A double blind, randomized, multicentric pilot study comparing differential effects on cognitive functioning in agitated-impulsive depression with two SSRIsPerrin, E. / Dalery, J. / Faruch, M. / Ammar, S. / Quintin, P. / Gourion, D. / Jouvent, R. / Dubal, S. et al. | 2003
- S229
-
P.1.131 Efficacy of reboxetine and amisulpride on cognitive functions in elderly inpatients with major depressive disorder and psychotic featuresVasile, D. / Ciurea, R. / Gheorghe, M. D. et al. | 2003
- S230
-
P.1.133 The use of antidepressants in bipolar depression: A retrospective and naturalistic studyMontes, J. M. / Asiel, A. / Lahera, C. / Sopelana, P. / Saiz-Ruiz, J. et al. | 2003
- S231
-
P.1.136 Pharmacotherapeutic trends of bipolar disorders in HungaryKovacs, G. et al. | 2003
- S232
-
P.1.138 Eye movement disturbances in patients with bipolar illnessKepa, A. / Borkowska, A. / Hauser, J. / Leszczynska, A. / Kosmowska, M. / Rybakowski, J. K. et al. | 2003
- S234
-
P.1.143 Simplified citalopram challenge test as a potentional depression markerSvarc, J. et al. | 2003
- S235
-
P.1.145 Efficacy and safety of mirtazapine in elderly depressed patientsYeon, B. K. / Oh, B. H. / Lee, M. S. / Lee, C. W. / Gee, B. S. / Ryu, S. G. et al. | 2003
- S237
-
P.1.149 Escitalopram for treatment of depression and anxiety disorder in adult outpatientsKlein, N. / Wiesegger, G. / Winkler, D. / Attarbaschi, T. / Mossaheb, N. / Kasper, S. / Tauscher, J. et al. | 2003
- S238
-
P.1.151 The effect of chronic lithium and lithium withdrawal on dopaminergic functionFerrie, L. / Young, A. H. / McQuade, r. et al. | 2003
- S239
-
P.1.154 Association study on the genetic polymorphism of the biogenic amine transporter gene family and antidepressant responsiveness in Korean depressed patientsKim, D. K. / Kwon, Y. A. / Lim, S. W. / Kim, H. et al. | 2003
- S241
-
P.1.159 A multi-dimensional approach to major depressionTacchini, G. / Fumagalli, S. / Fusi, O. / Altamura, A. C. et al. | 2003
- S242
-
P.1.161 Electroconvulsive therapy: Influence of the anaesthetic agentGarcia Mahia, M. et al. | 2003
- S243
-
P.1.164 Mood disorders and antidepressant treatment of prisoners with a history of self-mutilationLekka, N. P. / Beratis, S. et al. | 2003
- S244
-
P.1.166 A double-blind, randomized, steady-state, cross-over evaluation in healthy volunteers of the interaction of gepirone ER and paroxetineEreshefsky, L. / Lam, Y. W. / Tritsmans, L. / Timmer, C. J. / Dogterom, P. et al. | 2003
- S245
-
P.1.167 Chronic treatment with fluoxetine produced time realted alterations in opioid, cannabinoid and tirosine hydroxilase gene expression in selected regions of the rat brainOliva, J. M. / Uriguen, L. / Perez-Rial, S. / Ortiz, S. / Palomo, T. / Manzanares, J. et al. | 2003
- S246
-
P.1.170 A comparative study of serotonin transporter occupancy: In vivo 5-HT reuptake inhibitory potency and serum concentrations of antidepressants in miceLarsen, A. K. / Brennum, L. T. / Kreilgaard, M. / Sanchez, C. / Halldin, C. / Andersen, P. H. et al. | 2003
- S247
-
P.1.172 Bright light therapy in seasonal affective disorder - does it suffice?Pjrek, E. / Winkler, D. / Konstantinidis, A. / Thierry, N. / Heiden, A. / Kasper, S. et al. | 2003
- S248
-
P.1.174 Assessment of cerebral regions associated with sexual arousal in depressive women by using functional magnetic resonance imagingYang, J. C. / Lee, M. S. / Yoon, J. S. / Kang, H. K. / Jeong, G. W. / Kim, H. J. / Eun, S. J. / Zheng, T. J. et al. | 2003
- S251
-
P.1.181 Sexual function of patients with major depression treated with mirtazapine fast dissolving tablets or sertralineVan der Flier, S. / Vester-Blokland, E. et al. | 2003
- S253
-
P.1.186 Assessment of sexual dysfunction in depressive patients treated with sertralineTudor, C. / Grigorescu, G. / Ciurea, R. / Gheorghe, M. D. et al. | 2003
- S255
-
P.1.190 Prevalence and management of depression with painful physical symptoms in a Canadian claims databaseHopkins, J. / Gilsenan, A. W. / Corey-Lisle, P. / Longo, C. J. / Raskin, J. et al. | 2003
- S257
-
P.1.195 Effect of CRF1 receptor blockade on rat exploratory behaviour and AP-2 transcription factors in the locus coeruleus region: Important environmental and individual variablesHarro, J. / Mallo, T. / Berggard, C. / Eller, M. / Oreland, L. et al. | 2003
- S258
-
P.1.197 Long-term treatment with bupropion SR effectively prevents the relapse and recurrence of depressionGoodale, E. / Weihs, K. / Ascher, J. / Richard, N. / Metz, A. et al. | 2003
- S259
-
P.1.200 Red blood cell triiodothyronine uptake as membrane parameter of depressionStarkova, L. / Fisar, Z. / Paclt, I. / Vevera, J. et al. | 2003
- S260
-
P.1.202 Adverse effects of antidepressants and antipsychotics: A comparison between old and new generation drugs in a clinical naturalistic settingBarbato, G. / Casiello, M. / Muscettola, G. et al. | 2003
- S261
-
P.1.204 Duloxetine vs placebo in the prevention of relapse of major depressive disorderDetke, M. / Gilaberte, I. / Perahia, D. / Wang, F. / McNamara, R. / Tran, P. / Miner, C. / Montgomery, S. A. et al. | 2003
- S263
-
P.1.209 A comparison of remission rates based on HAM-D17 and the HAM-D subscales using MMRM and LOCF method for modeling the missing dataEntsuah, A. R. / Zhang, J. et al. | 2003
- S264
-
P.1.211 Burden of manic vs depressive symptoms in subjects with bipolar disorderHirschfeld, R. / Calabrese, J. / Frye, M. / Reed, M. / Wagner, K. et al. | 2003
- S265
-
P.1.214 Lamotrigine controls bipolar depression without destabilising mood: An analysis of data from 8 placebo-controlled trialsGrunze, H. / Calabrese, J. / Yatham, L. / Suppes, T. / McElroy, S. / Goldberg, J. F. / Bowden, C. et al. | 2003
- S266
-
P.1.216 Lamotrigine but not lithium prevents or delays depressive episodes in bipolar I disorderYatham, L. / Goodwin, G. / Bowden, C. / Calabrese, J. / White, R. / Leadbetter, R. et al. | 2003
- S272
-
P.1.230 Paroxetine improves general somatic symptoms associated with depressionDuff, D. / Christie, J. et al. | 2003
- S273
-
P.1.232 Menopausal depression: Comparing HRT and HRT plus fluoxetineLiu, P. / Yu, Q. / Bai, W. P. / He, F. F. / Shi, W. / Wu, Y. Y. / He, D. J. / Xiao, J. H. / Zheng, Y. / Liao, Q. P. et al. | 2003
- S275
-
P.1.237 Hypoalbuminemia in patients with major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutritionSu, K. P. / Chiu, C. C. / Huang, S. Y. et al. | 2003
- S276
-
P.1.239 Lithium and circadian rhythms of moving activity and temperature in rats with lesion of right and left suprachiasmatic nucleiZamoshchina, T. / Meleshko, M. / Matveenko, A. et al. | 2003
- S277
-
P.1.242 Gender differences in depressive symptoms among college students in BombayParikh, R. M. / Sonawalla, S. B. / Chakraborthy, N. / Mehra, G. / Dracass, S. / Fava, M. et al. | 2003
- S278
-
P.1.245 Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence and treatment response in depressionAkerblad, A. C. / Bengtsson, F. / Ekselius, L. / Von Knorring, L. et al. | 2003
- S279
-
P.2.002 The neural circuitry of persistent latent inhibition as a model of negative symptoms in schlophreniaSchiller, D. / Zuckerman, L. / Weiner, I. et al. | 2003
- S280
-
P.2.004 Homocysteine reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemiaShumeiko, O. / Levine, J. / Sela, B. A. / belmaker, R. H. et al. | 2003
- S281
-
P.2.006 Use and cost patterns of risperidone versus olanzapine for the treatment of schizophrenia: An assessment of medicaid children and adolescents age 5-18 yearsSclar, D. A. / Skaer, T. L. / Robison, L. M. / Dickson, W. M. / Markowitz, J. S. / De Vane, C. L. et al. | 2003
- S282
-
P.2.008 Remission of positive symptomatology of a schizophrenic psychosis after the discontinuation of lamotrigineStuve, W. / Wessels, A. / Timmerman, L. et al. | 2003
- S283
-
P.2.010 Differential involvement of the frontal lobe in patients with schizophrenia and schizotypal disorderSuzuki, M. / Zhou, S. Y. / Kawasaki, Y. / Hagino, H. / Takahashi, T. / Nohara, S. / Matsui, M. / Seto, H. / Kurachi, M. et al. | 2003
- S284
-
P.2.013 The influence of haloperidol on erythrocyte magnesium and plasma electrolytes in schizophrenic patientsNechifor, M. / Vaideanu, C. / Palamaru, I. / Borza, C. et al. | 2003
- S285
-
P.2.015 Atypical antipsychotics: Glutamate, amino acids and monoaminergic parametersVan der Heijden, F. M. / Tuinier, S. / Fekkes, D. / Sijben, A. E. / Kahn, R. S. / Verhoeven, W. M. et al. | 2003
- S286
-
P.2.019 Determinants of quality of life in patients with a first episode of schizophreniaGorna, K. / Jaracz, K. / Suwalska, A. et al. | 2003
- S287
-
P.2.021 Use of quetiapine in psychotic disorders. Evaluation of the effects of the treatment using the drug attitude inventory 30 (DAI-30)Cupillari, M. et al. | 2003
- S288
-
P.2.024 BIRD (bipolar disorder retrospective data): Switching antipsychotics in patients with bipolar disorder - reasons and outcomeLepage, B. / Hoekstra, R. / Morre, H. et al. | 2003
- S289
-
P.2.026 Is the drug-induced parkinsonism related to MRI-evident brain abnormality in psychosis?Maric, N. / Jasovic-Gasic, M. / Paunovic, V. R. et al. | 2003
- S290
-
P.2.028 Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patientsCorripio Collado, I. / Perez Sola, V. / Ferrer Vinardell, M. / Serra Buil, M. / EscartiXativa, M. J. / Alvarez Martinez, E. et al. | 2003
- S292
-
P.2.032 Latency period of risperidone, a study with 123I-IBZM spectOller, S. / Corripio Collado, I. / Perez-Egea, R. / Perez Sola, V. / Catafau, A. / Alvarez, E. et al. | 2003
- S295
-
P.2.038 Initial stages of insulin resistance in young antipsychotic-free and not in antipsychotic-naive schizophrenic patientsArranz, B. / Duenas, R. / Ramirez, N. / Fernandez, P. / Sarro, S. / San, L. et al. | 2003
- S296
-
P.2.041 High dose glycine added to olanzapine and risperidone for the treatment of schizophreniaErmilov, M. / Javitt, D. C. / Lichtenberg, P. / Bar, G. / Heresco-Levy, U. et al. | 2003
- S298
-
P.2.045 A family overloaded with psychosis and rickets-alopecia syndrome challenges vitamin-D hypothesis for schizophreniaOzer, S. / Ulusahin, A. / Ulusoy, S. / Okur, H. / Coskun, T. / Gogus, A. / Akarsu, A. N. et al. | 2003
- S299
-
P.2.048 Efficacy of intramuscular ziprasidone without adjunctive benzodiazepinesDaniel, D. G. / Brook, S. / Benattia, I. et al. | 2003
- S300
-
P.2.050 Varying degree of risks of developing new onset diabetes mellitus in patients treated with atypical antipsychoticsPajonk, F. G. et al. | 2003
- S301
-
P.2.053 Effect of acute and chronic treatment with the atypical antipsychotics olanzapine and clozapine in 8-radial arm maze in ratsOrtega-Alvaro, A. / Gibert-Rahola, J. / Mico, J. A. et al. | 2003
- S302
-
P.2.055 The influence of antipsychotic drug treatment on anticholinergic use and complexity of medication schemes in hospitalised pschotic patient in BelgiumDe Hert, M. / Wampers, M. / Fernandez, I. / Thys, E. / Wyckaert, S. / Peuskens, J. et al. | 2003
- S303
-
P.2.057 Clinical improvement with long-acting risperidone in patients previously receiving oral olanzapineJones, R. / Lasser, R. / Bossie, C. et al. | 2003
- S306
-
P.2.064 Managing schizophrenia in patients with co-morbid diabetes: A case report and literature reviewGreen, M. et al. | 2003
- S307
-
P.2.066 Effectiveness of antipsychotic treatments for patients from the Central Eastern Europe (CEE) region participating in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study: 6-month resultsPecenak, J. / Kaps, P. / Treuer, T. / Bitter, I. / Hodge, A. / Grigoriu, A. / Trzebiatowska, I. / Herman, E. / Peciukaitiene, D. / Smulevich, S. et al. | 2003
- S308
-
P.2.068 Antipsychotic treatment for schizophrenia: Effects on sexual functionOsvaldo, C. / Dossenbach, M. / Tamayo, J. M. / Soria, D. / Na, C. / Singh, S. / Wu, K. H. et al. | 2003
- S309
-
P.2.070 Treatment of resistant auditory hallucinations with quetiapine: Two case reports with cognitive assessmentMosolov, S. N. / Kabanov, S. et al. | 2003
- S310
-
P.2.072 A French cohort study on olanzapine prescription over a 12 months periodOlivier, V. / Fourrier, A. / Gasquet, I. / Flandre, P. / Perrin, E. et al. | 2003
- S311
-
P.2.074 Psychotropic polypharmacy among medicaid subjectsRupnow, M. / Markowitz, J. S. / Grogg, A. et al. | 2003
- S312
-
P.2.076 Strategies for assuring continuity of antipsychotic treatment at the interface between inpatient and outpatient treatment of patients with schizophreniaHamann, J. / Langer, B. / Kissling, W. et al. | 2003
- S313
-
P.2.078 Quetiapine improves symptoms and is well tolerated in patients with schizophrenia switched from olanzapineLarmo, I. et al. | 2003
- S314
-
P.2.080 Risperidone in the treatment of acute bipolar mania: A double-blind, placebo-controlled study of 290 patientsKhanna, S. / Vieta, E. / Lyons, B. / Grossman, F. / Kramer, M. et al. | 2003
- S315
-
P.2.083 Pilot study of the effects of rivastigmine in schizophreniaVan de Graaff, K. M. / Loonen, A. J. / Hovens, J. E. / Van Dijke, A. / Tulen, J. H. et al. | 2003
- S316
-
P.2.084 A comparison of olanzapine and risperidone for the schizophrenic patients intolerance of neuroleptic-induced extrapyramidal syndromes (EPS)Chan, H. Y. / Chen, C. H. / Chen, J. J. / Sun, H. J. / Chiu, H. J. / Chang, C. J. et al. | 2003
- S317
-
P.2.087 Risperidone monotherapy in acute bipolar maniaKramer, M. / Karcher, K. / Grossman, F. et al. | 2003
- S318
-
P.2.089 Switching from clozapine to zotepine in schizophrenic patients: A randomized, single-blind controlled studyLin, C. C. / Bai, Y. M. / Chen, J. Y. / Wang, Y. C. / Liou, Y. J. / Chao, C. H. / Lai, I. C. / Tsai, K. Y. / Chiu, H. J. et al. | 2003
- S319
-
P.2.091 Residential care in Italy. Preliminary clinical and psychosocial data of community living versus non-hospital residential facilities treated chronic schizophrenicsZizolfi, S. / Bargna, W. / Cilli, G. / Pirisi, R. et al. | 2003
- S320
-
P.2.093 Marked increase in adiposity during olanzapine vs risperidone treatment: Results of a placebo-controlled study in normal dogsAder, M. / Kim, S. P. / Catalano, K. J. / Ionut, V. / Hucking, K. / Richey, J. M. / Kabir, M. / Bergman, R. N. et al. | 2003
- S321
-
P.2.095 Atypical antipsychotics, weight gain, hyperglycemia, and lipid abnormalities: A two-year naturalistic studyUzun, O. / Cansever, A. / Aydyn, H. / Ozdemir, B. / Celik, C. et al. | 2003
- S322
-
P.2.097 The immune system abnormalities in first-episode schizophreniaSzulc, A. / Galinska, B. / Konarzewska, B. / Poplawska, R. / Czernikiewicz, A. et al. | 2003
- S323
-
P.2.100 Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: A comparative studyLis, S. / Krieger, S. / Gallhofer, B. / Torre, P. / Mittoux, A. / Menard, F. et al. | 2003
- S325
-
P.2.104 Hunting the susceptibility gene for psychosis: A study of a family overloaded with different forms of psychotic disordersOzer, S. / Ulusoy, S. / Okur, H. / Gogus, A. / Akarsu, A. N. / Ulusahin, A. et al. | 2003
- S326
-
P.2.106 Change in clinical status and quality of life of schizophrenic patients in Germany: Six month results from the schizophrenia outpatient health outcomes (SOHO) studyNaber, D. / Krausz, M. / Dittmann, R. W. / Mahl, C. / Langer, F. / Wagner, T. / Linder, P. / Novick, D. / Czekalla, J. et al. | 2003
- S327
-
P.2.109 A double-blind placebo-controlled trial of risperidone in autistic disorderMcDougle, C. J. / Aman, M. G. / McCracken, J. T. / Scahill, L. / Tierney, E. / Vitiello, B. et al. | 2003
- S328
-
P.2.112 Clozapine decreases tyrosine hydroxylase level in PC12 cells by a Gi/Go protein dependent presynaptic mechanismsTejedor-Real, P. / Faucon Biguet, N. / Mallet, J. et al. | 2003
- S331
-
P.2.118 SPECT quantification of in vivo dopamine D2 receptor occupancy with risperidone microspheresWiesegger, G. / Klein, N. / Asenbaum, S. / Attarbaschi, T. / Mossaheb, N. / Dudczak, R. / Kasper, S. / Tauscher, J. et al. | 2003
- S332
-
P.2.120 Time of dosing and food effect on aripiprazole pharmacokineticsMallikaarjun, S. / Riesgo, Y. / Salazar, D. / Bramer, S. / Xie, J. / Weston, I. et al. | 2003
- S333
-
P.2.123 Atypical antipsychotic treatment-related urinary incontinence: A urodynamic evaluationMartino, G. / Isgro, S. / Di Rosa, E. / Zoccali, R. / Citto, G. / Meduri, M. et al. | 2003
- S334
-
P.2.126 Evidence for aspartate as a neurotransmitter in the mediodorsal thalamus-medial prefrontal cortex pathwayGlennon, J. / O'Connor, W. T. et al. | 2003
- S335
-
P.2.128 Metabolic effects associated with antipsychotic therapy in a naturalistic settingSchreinzer, D. / Letmaier, M. / Barnas, C. / Kasper, S. et al. | 2003
- S338
-
P.2.136 Premorbid functioning and outcomes in recent onset schizophreniaRabinowitz, J. / De Smedt, G. / Davidson, M. et al. | 2003
- S339
-
P.2.138 Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychoticsHardy, T. / Sowell, M. O. / Marquez, E. / Cavazzoni, P. / Taylor, C. C. / Breier, A. et al. | 2003
- S341
-
P.2.143 Extrapyramidal symptoms after six months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) studyWright, P. / Haro, J. M. / Frewer, P. / Novick, D. / Edgell, E. T. et al. | 2003
- S342
-
P.2.145 The effectiveness of olanzapine versus plasma in maintaining the quality of life in stabilized patients with schizophreniaBeasley Jr, C. M. / Walker, D. J. / Sutton, V. K. / Alaka, K. / Naber, D. / Namjoshi, M. et al. | 2003
- S343
-
P.2.148 Dissociation of amygdala and visual cortex sensitivity for unpleasant facial expression in first-episode schizophrenic patients: An fMRI studyStrous, R. / Bleich, M. / Even, R. / Harari, H. / Pianka, P. / Rotshtein, P. / Kotler, M. / Hendler, T. et al. | 2003
- S344
-
P.2.150 Ziprasidone in adjunctive treatment of acute bipolar mania: A randomized, double-blind placebo-controlled trialWeisler, R. H. / Dunn, J. / English, P. et al. | 2003
- S345
-
P.2.152 Ziprasidone in mania: A 21-day randomized, double-blind, placebo controlled trialSegal, S. / Riesenberg, R. A. / Ice, K. / English, P. et al. | 2003
- S346
-
P.2.154 Quality of life and health status of previously untreated schizophrenic patients over the first 6 months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) studyGasquet, I. / Haro, J. M. / Novick, D. / Frewer, P. / Tzivelekis, S. / Tcherny-Lessenot, S. et al. | 2003
- S347
-
P.2.156 Atypical versus typical antipsychotic treatment prognosis based on VEPs and WCST scores in paranoid schizophreniaMazurek, I. / Loza, B. / Lecyk, A. et al. | 2003
- S348
-
P.2.158 Donepezil as an adjunctive treatment of cognitive dysfunction in schizophreniaTuma, M. / Lenderova, Z. / Zemanova, M. / Kadlecova, E. / Perez, M. et al. | 2003
- S350
-
P.2.162 Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: Interim results of a randomised, rater-blinded studySacchetti, E. / Valsecchi, P. / Regini, C. / Galluzzo, A. / Cacciani, P. / Agrimi, E. / Mencacci, C. et al. | 2003
- S351
-
P.2.165 Viral infection and neurodevelopmental (animal) model of schizophrenia: Effects of antipsychoticsTejkalova, H. / St'astny, F. / Klaschka, J. et al. | 2003
- S353
-
P.3.001 Increased hypothalamic-pituitary adrenal axis activity in children with anxiety disorders and matched controlsVan West, D. / Claes, S. / Sulon, J. / Deboutte, D. et al. | 2003
- S356
-
P.3.007 Photosensitivity and affective disorders: Relationship with anxiety symptomatologyMartinucci, M. / Bossini, L. / De Capua, A. / Paolini, K. / Castrogiovanni, P. et al. | 2003
- S357
-
P.3.009 Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIsAlbert, U. / Maina, G. / Forner, F. / Bogetto, F. et al. | 2003
- S358
-
P.3.011 Reduced brain serotonin transporter binding in patients with panic disorderMaron, E. / Kuikka, J. T. / Shlik, J. / Vasar, V. / Vanninen, E. / Tiihonen, J. et al. | 2003
- S359
-
P.3.014 Stress increases susceptibility to oxidative damage in an experimental model of colitis in ratsLeza, J. C. / Colon, A. / Madrigal, J. L. / Menchen, L. / Hurtado, O. / Moro, M. A. / Lizasoain, I. / Lorenzo, P. et al. | 2003
- S360
-
P.3.016 The antiepileptic drug levetiracetam displays an anxiolytic profile in the potentiated startle paradigm in the ratLamberty, Y. / Green, S. / Vale, A. / Gower, A. J. / Klitgaard, H. et al. | 2003
- S361
-
P.3.019 Differences in beta-adrenergic receptor sensitivity between female and male with panic disorderKim, Y. R. / Min, S. K. / Yu, B. H. et al. | 2003
- S362
-
P.3.022 Role of GABA/benzodiazepine receptors of the dorsal periaqueductal grey of rats in the mediation of innate and conditioned anxiety responsesDe Barros Viana, M. / Bueno, C. / Zangrossi Jr, H. et al. | 2003
- S363
-
P.3.024 Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuseStein, D. J. / Van der Kolk, B. / Austin, C. / Fayyad, R. / Clary, C. et al. | 2003
- S364
-
P.3.027 Activity in the fear-potentiated startle (FPS) in rodents and healthy subjects with LY354740, a novel mGlu2/3 receptor agonistLevine, L. / Landbloom, R. P. / Schoepp, D. D. / Tizzano, J. P. / Grillon, C. et al. | 2003
- S365
-
P.3.029 Efficacy of sertraline in improving quality of life and functioning in generalized anxiety disorder (GAD)Sjodin, I. / Kutcher, S. P. / Ravindran, A. / Butt, T. et al. | 2003
- S366
-
P.3.031 A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of PTSDOnder, E. / Tural, U. / Aker, T. et al. | 2003
- S367
-
P.3.034 Joint hypermobility syndrome in panic disorder patients with and without mitral valve prolapseGulpek, D. / Bayraktar, E. / Pyryldar, S. / Capacy, K. / Kayykcyoglu, M. / Aliyev, E. / Soydas, C. et al. | 2003
- S368
-
P.3.036 Psychosocial sequelae of the 1998 Ceyhan-Adana earthquake. A prospective studyUguz, S. / Seydioglu, G. et al. | 2003
- S369
-
P.3.038 Escitalopram versus placebo in Social Anxiety Disorder (SAD): Better effectiveness, lower costs and improved quality of lifeMontgomery, S. A. / Francois, C. / Despiegel, N. et al. | 2003
- S370
-
P.3.041 Effects of SKF 10047, a sigma selective agonist, on anxiety tested in the elevated plus maze in male miceBeltran, D. / Cavas, M. / Navarro, J. F. et al. | 2003
- S374
-
P.3.050 Pooled analysis of symptom-free days in generalized anxiety disorderWan, G. / Zhang, H. F. et al. | 2003
- S376
-
P.3.054 Pregabalin in generalized anxiety disorder: Speed of onsetMontgomery, S. A. et al. | 2003
- S377
-
P.3.057 Treatment of panick disorder with venlafaxine XRAhokas, A. / Bradwejn, J. / Emilien, G. / Whitaker, T. et al. | 2003
- S378
-
P.3.059 The reinstatement of conflict reverses the one-trial tolerance to diazepam on elevated plus-mazeAndreatini, R. / Vital, M. A. / Santos, G. L. et al. | 2003
- S379
-
P.3.061 A meta-analysis of the acute effect of buspirone on elevated plus-maze: A preliminary reportAndreatini, R. / Souza, M. N. / Boerngen-Lacerda, R. et al. | 2003
- S380
-
P.3.063 Long-term treatment of generalized social anxiety disorder with venlafaxine XRHackett, D. / Stein, M. B. / Mangano, R. / Pollack, M. et al. | 2003
- S381
-
P.3.065 Patient-reported functioning in SAD and improvement with treatment: A comparison of venlafaxine XR, paroxetine, and placeboBaldwin, D. / DeMartinis, N. / Mallick, R. et al. | 2003
- S382
-
P.3.067 Decreased lymphocyte 3H-paroxetine binding in obsessive-compulsive disorderMasala, I. / Baroni, S. / Betti, L. / Giannaccini, G. / Mungai, F. / Marazziti, D. et al. | 2003
- S383
-
P.3.069 Placebo response and anxiety disorders: A critical evaluation of influential variablesWilcox, C. S. / Katz, B. B. / Heiser, J. F. / Cho, F. E. / Morrissey, J. L. / Grosz, D. E. / Hardy, A. I. / DeFrancisco, D. F. et al. | 2003
- S384
-
P.3.071 Paroxetine improves somatic symptoms associated with panic disorder and GADStein, D. J. / Christie, J. / Duff, D. et al. | 2003
- S385
-
P.3.073 The novel and selective 5-HT1B receptor antagonist SB-616234-A increases extracellular 5-HT and displays anxiolytic efficacy in guinea pigsHughes, Z. A. / Bettelini, L. / Trail, B. / Arban, R. / Dawson, L. A. et al. | 2003
- S386
-
P.4.001 Faster forgetting of spatial memory in the PDAPP mouse-model of Alzheimer's diseaseSandin, J. / Chen, G. / Martin, S. J. / Chen, K. S. / Morris, R. G. et al. | 2003
- S387
-
P.4.003 Multi-segmental late onset idiopathic dystonia presenting as tardive dyskinesia and treated with quetiapineMayze, T. D. / O'Sullivan, J. et al. | 2003
- S388
-
P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's diseaseMoebius, H. J. / Reisberg, B. / Schmitt, F. / Doody, R. et al. | 2003
- S389
-
P.4.008 Effects of galanthamine and donepezil on model of aging brain in ratsDimitrova, D. / Getova, D. et al. | 2003
- S390
-
P.4.010 Effects of galantamine on the motor and avacuative functions of rat's gastrointestinal tract. In Vivo and in vitro studyKrastev, A. / Turiiski, V. / Sirakov, V. / Getova, D. et al. | 2003
- S391
-
P.4.013 GSK3b over-expressing mice - a mouse model for Alzheimer's disease?Schott, P. A. / Rask, A. / Nilsson, Y. / Staflund, A. / Bhat, R. V. et al. | 2003
- S392
-
P.4.016 Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer's diseaseTanila, H. / Minkeviciene, R. / Banerjee, P. et al. | 2003
- S393
-
P.4.018 Memantine restores okadaic acid-induced changes in the activities of protein phosphatase-2A, CaMKII and hyperphosphorylation of tau in rat hippocampal slices in cultureIqbal, K. / Li, L. / Sengupta, A. / Grundke-Iqbal, I. et al. | 2003
- S394
-
P.4.021 Acetylcholinesterase inhibitor, donepezil, is a potent antagonist of potassium channels of neuronal membraneSolntseva, E. / Bukanova, J. V. et al. | 2003
- S395
-
P.4.024 Broad spectrum of clinical benefits from galantamine confirmed in large-scale observational study of Alzheimer's disease in SwitzerlandHeld, C. et al. | 2003
- S396
-
P.4.026 Hippocampal galanin and acetylcholine in spatial learning of the ratElvander, E. / Yoshitake, T. / Kehr, J. / Sandin, J. / Ogren, S. O. et al. | 2003
- S397
-
P.4.028 Efficacy of bio-normalizer in stroke patients: EEG-mapping, neuropsychological and clinical studyZhavoronkova, L. / Maksakova, O. A. et al. | 2003
- S398
-
P.4.032 Cognitive influence of topiramate in childrenQuin, F. J. / del Alamo, G. G. / Rebollo, M. J. / Corredoira, P. / Gomez, R. I. / Garcia, E. B. / Quintero Lumbreras, F. J. et al. | 2003
- S399
-
P.4.034 Neuropsychiatric symptoms in APOE genotyped Alzheimer's disease patients: Contributions to diagnosis and prognosis of the diseaseAlvarez, A. / Laredo, M. / Couceiro, V. / Fernandez-Novoa, L. / Sampedro, C. / Cacabelos, R. / Vargas, M. / Aleixandre, M. et al. | 2003
- S400
-
P.4.037 Tic reduction in Tourette's disorder with olazapineNaudts, K. / Dhondt, K. / Sieben, A. / Van den Eynde, F. / Audenaert, K. / Van Heeringen, C. et al. | 2003
- S401
-
P.4.039 In vivo characterization of a novel compound 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-ylamine (ST 1535), a selective adenosine A2A antagonistStasi, M. A. / Di Pasquale, M. P. / Di Cesare, M. A. / Minetti, P. / Pacifici, L. / Carminati, P. et al. | 2003
- S402
-
P.4.041 Donepezil is a well-tolerated long-term treatment for patients with mild to moderate Alzheimer's disease: Results from a patient cohort who completed a one-year placebo-controlled study and participated in a two-year follow-up studyWinblad, B. / Engedal, K. / Soininen, H. / Verhey, F. R. / Waldemar, G. / Wimo, A. / Wetterholm, A. L. / Haglund, A. / Zhang, R. / Burger, L. et al. | 2003
- S403
-
P.4.043 DemTect: Final English version of a new cognitive screening test for mild cognitive impairment and early dementiaKessler, J. / Kalbe, E. / Calabrese, P. / Smith, B. / Passmore, P. / Bullock, R. et al. | 2003
- S404
-
P.4.045 Dementia patients with additional parkinsonian symptoms benefit from donepezil therapyKohler, J. / Jendroska, K. / Horn, R. / Kamleiter, M. / Mobius, J. / Reipe, M. et al. | 2003
- S408
-
P.4.055 Neurological development of infants exposed to benzodiazepines in uteroCerovac Cosic, N. / Proctran, M. / Jovic, N. / Gligorovic, S. / Todorovic, S. et al. | 2003
- S409
-
P.5.003 Metoclopramide and ondansetron prn during multidrug withdrawalMiozzari, A. / Rajeswaran, R. / Zimmermann, G. / Krenz, S. / Zullino, D. F. et al. | 2003
- S410
-
P.5.006 Evaluation of using the biological markers ethyl glucuronide, carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume as an indicator of alcohol abuse and abstinenceEmara, A. et al. | 2003
- S411
-
P.5.009 Buprenorphine: A new pharmacological option for heroin addicts' treatmentGuglielmino, L. / Vigezzi, P. / Silenzio, R. / De Chiara, M. / Corrado, F. / Marzorati, P. / Cocchi, L. / Cozzolino, E. et al. | 2003
- S412
-
P.5.011 Individual reactivity to a novel environment predicts differences in anxiety-like behaviours and in morphine-induced locomotor sensitisation and tolerance in the ratKalinichev, M. / White, D. A. / Holtzman, S. G. et al. | 2003
- S413
-
P.5.014 Diazepam in combination with piracetam in the treatment of alcohol withdrawal syndromeLazarova, V. / Jakovcevska-Kujundziska, M. / Filovska, V. et al. | 2003
- S414
-
P.5.016 Effects of nitric oxide synthase inhibitor L-NOARG on behaviour in mice after chronic ethanol inhalationPokk, P. / Okva, K. / Lang, A. / Sepp, E. / Vali, M. / Nevalainen, T. et al. | 2003
- S415
-
P.5.018 Temperamental traits in multiaddictive behaviorsDervaux, A. / Bayle, F. J. / Krebs, M. O. / Lejoyeux, M. / Ades, J. et al. | 2003
- S416
-
P.5.021 Inhibition of cannabinoid CB1 receptor attenuates behavioural sensitization to methamphetamine in miceLanda, L. / Slais, K. / Sulcova, A. et al. | 2003
- S418
-
P.5.027 C-fos expression after cocaine or morphine sensitization in CB1 knockout miceMurtra, P. / Martin, M. / Ledent, C. / Patmentier, M. / Maldonado, R. et al. | 2003
- S419
-
P.5.030 Substance use disorders and their treatment response in dual diagnosis bipolar disorderCalabrese, J. / Shelton, M. / Elhaj, O. / Rapport, D. / Youngstrom, E. / Packer, K. / Sak-Jackson, K. / Bilali, S. / Findling, R. et al. | 2003
- S420
-
P.5.033 Apolipoprotein E epsilon 4 is associated with hippocampal volume reduction in females with alcoholismBleich, S. / Wilhelm, J. / Degner, D. / Sperling, W. / Kornhuber, J. et al. | 2003
- S421
-
P.5.036 Dependence on tramadol - a case seriesPaiva, A. / Lobo, M. / Chainho, J. et al. | 2003
- S422
-
P.5.039 Influence of serotonin 5-HT2A and 5 HT2C receptor agonists and antagonists on the locomotor and discriminative stimulus effects of cocaine or direct dopamine D1-like and D2-like receptor agonistsFilip, M. / Cunningham, K. A. et al. | 2003
- S423
-
P.5.041 Differential actions of nicotinic agonists on exploratory behaviour in ratsMoore, N. / Nunan, R. / Greenhalgh, C. / Rees, G. / Tree, B. et al. | 2003
- S425
-
P.5.046 Mirtazapine and venlafaxine administration in alcohol detoxification: Impact on anxiety and depression symptomsTzavellas, E. / Liappas, J. / Kontoangelos, C. / Paparrigopoulos, T. / Christodoulou, G. N. et al. | 2003
- S426
-
P.5.048 Effects of fluoxetine on ethanol withdrawal syndrome in ratsKayir, H. / Saglam, E. / Celik, T. / Beyazyurek, M. / Uzbay, I. T. et al. | 2003
- S427
-
P.6.001 Relationships between DRD2 and DAT polymorphisms and personality traits in healthy subjectsPinto, E. / Reggers, J. / Hansenne, M. / Pitchot, W. / Fuchs, S. / Gorwood, P. / Vaira, D. / Ansseau, M. et al. | 2003
- S429
-
P.6.007 Acute and subchronic effects of gammahydroxybutyrate (GHB) on isolation induced aggression in male miceNavarro, J. F. / Gonzalez, F. / Pedraza, C. et al. | 2003
- S430
-
P.6.009 Possible psychosocial factors for sexual dysfunctions of Turkish males: A descriptive studyUguz, S. / Soylu, M. L. et al. | 2003
- S431
-
P.6.011 Subtypes of autism by cluster analysis based on structural MRI dataHrdlicka, M. / Dudova, I. / Beranova, I. / Lisy, J. / Belsan, T. / Neuwirth, J. / Komarek, V. / Faladova, L. / Sedlacek, Z. / Havlovicova, M. et al. | 2003
- S432
-
P.6.014 The frequency and associated factors of excessive daytime sleepiness in Korean young menLee, S. P. / Hong, S. C. / Han, J. H. / Jeong, J. H. / Lim, S. H. et al. | 2003
- S434
-
P.6.020 Association of the TAP2 gene with schizophrenia in the Korean populationJun, T. Y. / Lee, K. U. / Song, J. M. / Pae, C. U. / Chae, J. H. / Bahk, W. M. / Kim, K. S. et al. | 2003
- S435
-
P.6.023 Association study of dopamine system genes in anorexia nervosaSlopien, A. / Rybakowski, F. / Dmitrzak-Weglarz, M. / Hauser, J. / Rajewski, A. et al. | 2003
- S436
-
P.6.026 Caffeine influenced time-perception in humansGhita Cristescu, I. / Comar, O. / Savo, O. / Rotar, C. / Fulga, I. et al. | 2003
- S438
-
P.6.031 An association of the serotonin receptor (5HT2A) gene and serotonin transporter (5HTTLPR) gene in anorexia nervosaDmitrzak-Weglarz, M. / Rybakowski, F. / Slopien, A. / Czerski, P. / Hauser, J. / Rajewski, A. et al. | 2003
- S439
-
P.6.033 Decline in CYP2D6 metabolising capacity in the elderlyTandon, K. / Kinirons, M. / Patel, M. / McGuffin, P. / Aitchison, K. J. et al. | 2003
- S440
-
P.6.035 Diffusion-weighted MRI study of corpus callosum in patients with schizophrenia. Preliminary findingsBrambilla, P. / Cerini, R. / Barbui, C. / Gasparini, A. / Nose, M. / Versace, A. / Vittom, E. / Andreone, N. / Gregis, M. / David, A. et al. | 2003
- S441
-
P.6.037 Effect of 5-HT2C receptor activation on reward and loss response patterns in humans detected by fMRIStirling, J. / Vollm, B. / Richardson, P. / Del Ben, C. / Elliott, R. / Anderson, I. / McKie, S. / Deakin, B. / Williams, W. et al. | 2003
- S442
-
P.6.039 Correlation of brain perfusion and cognitive functions in sleep apnea patients: A study with Tc-99m HMPAO in sleep laboratoryKiratli, P. / Volkan, B. / Demir, A. / Demir, B. / Sahin, A. et al. | 2003
- S444
-
P.6.044 Repetition of suicidal behaviour following deliberate self-poisoning with pesticidesNaudts, K. / Portzky, G. / Audenaert, K. / Van Heeringen, C. et al. | 2003
- S446
-
P.6.049 General practitioners' attitudes towards psychotic disorders and their treatment in primary health care system in TurkeyYildiz, M. / Onder, M. E. / Tural, U. / Balta, H. I. / Kocalim, N. et al. | 2003
- S447
-
P.6.052 Evaluation of once-daily OROS methylphenidate in children with attention-deficit/hyperactivity disorder Effects on sleep, approach and ticsBiederman, J. et al. | 2003
- S448
-
P.6.054 Treatment of attention-deficit/hyperactivity disorder with the once daily OROS formulation of methylocnidate: Effect on growth in childrenBiederman, J. et al. | 2003
- S449
-
P.6.056 Minor physical anomalies in Tourette syndromeTenyi, T. / Gadoros, J. / Csabi, G. / Jeges, S. / Gyenge, E. / Trixler, M. et al. | 2003
- S450
-
P.6.059 Leptin and glucose metabolism in eating disordersGati, A. / Tury, F. / Wittmann, I. et al. | 2003
- S451
-
P.6.061 Treatment of children with attention deficit/hyperactivity disorder: Evaluating switch from conventional methylphenidate to the once-daily OROS formulation of methylphenidateSantosh, P. et al. | 2003
- S452
-
P.6.064 Evaluating venlafaxine treatment for chronic painDemitrack, M. / Kunz, N. / Entsuah, A. R. et al. | 2003
- S453
-
P.6.066 Effects of risperidone versus placebo on aggression in children with disruptive behaviour disordersBinder, C. / Hew, H. / Kusumakar, V. / LeBlanc, J. / Wang, J. et al. | 2003
- S454
-
P.6.068 Once-daily atomoxetine in childhood ADHD: Continuous symptom reliefAllen, A. J. / Kelsey, D. / Sumner, C. / Sutton, V. K. / Gonzales, J. / Malcolm, S. / Schuh, K. / Michelson, D. et al. | 2003
- S455
-
P.6.070 Atomoxetine in the long-term prevention of relapse in ADHDMichelson, D. / Buitelaar, J. / Danckaerts, M. / Gillberg, C. / Spencer, T. J. / Zuddas, A. / Zhang, S. / Biederman, J. et al. | 2003
- S456
-
P.6.072 Placebo-controlled study of once-daily atomoxetine in the school settingWeiss, M. / Tannock, R. / Kratochvil, C. / Dunn, D. / Velez-Borras, J. / Thomason, C. / Lambrecht, L. / Tamura, R. / Kelsey, D. / Allen, A. J. et al. | 2003
- S457
-
P.6.074 Effects of lamotrigine on quality of life in patients with bipolar I disorderRapaport, M. / Kennedy, S. / Davis, K. et al. | 2003
- S458
-
P.6.077 Long-term effects of atomoxetine on growth in children with APHDMichelson, D. / Spencer, T. / Ruff, D. / Feldman, P. D. et al. | 2003
- S459
-
P.6.080 Long-term exposure to lithium therapy and side effects with common dosingFilovska, V. / Jakovcevska-Kujundziska, M. / Lazarova, M. / Krsteska, R. et al. | 2003
- S460
-
P.6.082 An open case study in Italy of oxcarbazepine, an effective mood stabiliser, in patients with drug resistant/intolerant bipolar I disorderFrare, F. / Perugi, G. / Toni, C. / Ruffolo, G. / Akiskal, H. S. et al. | 2003
- S461
-
P.6.084 Apolipoprotein E genotype in Korean schizophrenic patientsNam, B. W. / Seo, J. S. et al. | 2003
- S462
-
P.6.087 Executive functions in remitted schizophrenic patients: A preliminary studySaba, G. / Verdon, C. M. / Moulier, V. / Dumortier, G. / Kalalou, K. / Rocamora, J. F. / Benadhira, R. / Stamatiadis, L. / Januel, D. et al. | 2003
- S463
-
P.6.089 Chromosome 3q29: Follow-up linkage analysis in schizophrenia and bipolar disorderSchosser, A. / Fuchs, K. / Leisch, F. / Bailer, U. / Kasper, S. / Sieghart, W. / Hornik, K. / Aschauer, H. N. et al. | 2003
- S464
-
P.6.091 Follow-up study of the effects of carbamazepine in the treatment of impulsiveness in patients with personality disordersTodorovic, M. / Timotijevic, I. et al. | 2003
- S467
-
Author index| 2003
- S483
-
Keyword index| 2003
-
S.06.02 Imaging dopamine synaptic activity with PETLaruelle, M. et al. | 2003
-
S.12.03 Physiological regulation of a7 nicotinic receptor activity by endogenous levels of the brain metabolite kynurenic acid: Clinical implicationsSchwarcz, R. / Pereira, E. F. / Alkondon, M. / Almeida, L. E. / Fawcett, W. P. / Randall, W. R. / Guidetti, P. / Sapko, M. T. / Yu, P. / Tagle, D. A. et al. | 2003
-
S.20.03 Neuroendocrinological modulation of reward systems and vulnerabilityLe Moal, M. / Marinelli, M. / Deroche-Gamonet, V. / Piazza, P. V. et al. | 2003
-
S.27.05 Nicotine and dopamine D3 receptor: Implications in drug addiction and Parkinson's diseaseLe Foll, B. / Diaz, J. / Schwartz, J. C. / Sokoloff, P. et al. | 2003
-
P.1.028 Typical neuroleptics versus atypical antipsychotics in the treatment of acute mania in a natural settingLetmaier, M. / Schreinzer, D. / Reinfried, L. / Glauninger, G. / Thierry, N. / Kapitany, T. / Kasper, S. et al. | 2003
-
P.1.033 Analysis of gepirone ER on the bech-6 and individual hamD-17 item scoresSchutte, A. J. / Gibertini, M. / Simmons, J. H. et al. | 2003
-
P.1.075 Effect of combined treatment with imipramine and metyrapone on the immunological and endocrine parameters of rats subjected to the forced swimming testRogoz, Z. / Skuza, G. / Kubera, M. / Basta-Kaim, A. / Budziszewska, B. / Jaworska-Feil, L. / Tetich, M. et al. | 2003
-
P.1.086 R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxietySanchez, C. / Bien, E. / Gruca, P. et al. | 2003
-
P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trialEvans, A. / Tohen, M. / Marneros, A. / Bowden, C. / Greil, W. / Koukopoulis, A. / Belmaker, R. H. / Jacobs, T. / Baker, R. / Williamson, D. et al. | 2003
-
P.1.115 CLOCK gene and circadian mood fluctuations in bipolar depressionBenedetti, F. / Serretti, A. / Colombo, C. / Barbini, B. / Lorenzi, C. / Campori, E. / Smeraldi, E. et al. | 2003
-
P.1.119 Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphismBenedetti, F. / Serretti, A. / Mandelli, L. / Lorenzi, C. / Pirovano, A. / Colombo, C. / Smeraldi, E. et al. | 2003
-
P.1.137 Autoimmune thyroiditis (AIT) and affective disorders - a prospective pilot studyDegner, D. / Bleich, S. / Haust, M. / Zerr, I. / Ruther, E. / Meller, J. et al. | 2003
-
P.1.152 An appropriate strategy for screening antidepressant drugs using the mouse forced swimming test and the tail suspension testChenu, F. / Nic Dhonnchadha, B. A. / Ripoll, N. / David, D. J. / Hascoet, M. / Bourin, M. et al. | 2003
-
P.1.155 Remission of early responders in patients with major depression treated with mirtazapineSuh, H. S. / Kim, C. H. / Lee, H. S. / Koo, M. S. et al. | 2003
-
P.1.158 SSRIs increase 5-HT2A receptor binding in depressed patients: A SPECT studyD'haenen, H. / Schins, A. et al. | 2003
-
P.1.185 Does pretreatment anxiety or insomnia predict acute response to bupropion SR?Rush, A. J. / Schmid, R. / Haight, B. / Zisook, S. / Rockett, C. / Carmody, T. et al. | 2003
-
P.1.196 Effects of bupropion SR on body weight and depressive symptoms in obese patients treated for 50 weeksGoodale, E. / Bradley, P. / Haight, B. / Foster, V. / Richard, N. / Modell, J. et al. | 2003
-
P.1.207 Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorderBielski, R. / Ventura, D. / Chang, C. / Korotzer, A. et al. | 2003
-
P.1.217 Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorderKetter, T. / Bowden, C. / Vieta, E. / Goldberg, J. F. / Antonijevic, Z. / Leadbetter, R. et al. | 2003
-
P.1.222 NK1 receptors in human blood lymphocytes and granulocytesBaroni, S. / Masala, I. / Giusti, L. / Betti, L. / Giannaccini, G. / Marazziti, D. et al. | 2003
-
P.2.040 Size matters: The impact of the volume of the amygdala on its activation during the processing of facial expressions of fearShaw, P. / Kucharska-Pietura, K. / Russell, T. / Zelaya, F. / Amaro, E. / Phillips, M. L. / David, A. S. et al. | 2003
-
P.2.067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophreniaKasper, S. / Lowry, A. J. / Hodge, A. / Bitter, I. / Dossenbach, M. et al. | 2003
-
P.2.079 Open-label study of risperidone in children with bipolar disorderBiederman, J. et al. | 2003
-
P.2.043 Treatment of acutely exacerbated including highly agitated schizophrenic patients with oral risperidoneSchreiner, A. / Pajonk, F. G. / Peters, S. / Ruether, E. et al. | 2003
-
P.2.125 A six-month, double-blind, controlled trial in schizophrenic patients comparing amisulpride and olanzapineMortimer, A. / Rein, W. / Fleurot, O. et al. | 2003
-
P.2.127 Aripiprazole in pediatric-conduct disorder: A pilot studyFindling, R. L. / Blumer, J. L. / Kauffman, R. / Batterson, J. R. / Gilbert, D. L. / Bramer, S. / Marcus, R. et al. | 2003
-
P.3.006 Effects of cannabidiol (CBD) on regional cerebral blood flowZuardi, A. / Crippa, J. A. / Garrido, G. E. / Wichter-Ana, L. / Guarnieri, R. / Ferrari, L. / Marques, P. M. / Hallak, J. E. / Mc Guire, P. K. / Busato, G. F. et al. | 2003
-
P.3.021 Selective AMPA receptor antagonist GYKI 52466 is effective in three animal models of anxietyKapus, G. / Gacsalyi, I. / Vegh, M. / Levay, G. et al. | 2003
-
P.3.049 Decreased temporal lobe volume in panic disorder - a quantitative morphometric MRI studySobanski, T. / Wagner, G. / Gruhn, U. / Schluttig, K. / Tauber, R. / Peikert, G. / Sauer, H. et al. | 2003
-
P.3.060 Efficacy of sertraline in treating psychic and somatic symptoms in generalized anxiety disorder (GAD)Ravindran, A. / Dahl, A. A. / Allgulander, C. / Burt, T. et al. | 2003
-
P.3.070 CCK2 receptor deficient mice: Changes in anxiety and pain sensitivityVasar, E. / Koks, S. / Abramov, U. / Innos, J. / Raud, S. / Kurrikoff, K. / Volke, V. / Bourin, M. / Matsui, T. et al. | 2003
-
P.4.033 Phospholipase D platelet activity in patients with dementia and acute ischaemic strokeKrzystanek, E. / Opala, G. / Trzeciak, H. I. / Krzystanek, M. / Suida, J. et al. | 2003
-
P.5.002 The effects of beta-adrenergic receptors on the acquisition of nicotine-induced conditioned place preference in miceZardooz, H. / Sahraei, H. / Oryan, S. / Zarrindast, M. R. / Hossein-Mardi, L. et al. | 2003
-
P.5.013 Health, general functioning and psychopathology in patients treated with methadone and LAAMCavaglia, F. / Goncalves, N. / Borges, G. / Pires-Barreira, D. / Matos-Pires, A. et al. | 2003
-
P.5.037 Craving treatment: The role of citalopram and paroxetineCampana, M. / Riglietta, M. / Crocco, A. / Nava, M. et al. | 2003
-
P.5.035 Frequency and causes of premature termination during in-patient opiate detoxificationHeiden, A. / Baecker, C. / Frey, R. / Presslich, O. / Kasper, S. et al. | 2003
-
P.6.003 Reduced hypothalamic-pituitary adrenal axis activity in children with attention deficit hyperactivity disorder and matched controlsVan West, D. / Claes, S. / Sulon, J. / Deboutte, D. et al. | 2003
-
P.6.029 Fractal analysis of magnetic resonance images in schizophrenia and obsessive-compulsive disorderKwon, J. S. / Yoon, U. / Lee, J. M. / Ha, T. H. / Kim, L. Y. / Kim, S. I. et al. | 2003
-
P.6.090 Alexithimia anxiety and depression in patients with bronchial asthmaKarkanias, A. / Moussas, G. / Stamouli, D. / Tselebis, A. / Bakogianni, T. et al. | 2003
-
Editorial Board| 2003
-
S.25.01 Psychotropic drugs in the prevention of suicideIsacsson, G. et al. | 2003
-
S.28.02 Neuropeptide Y (NPY) in anxiety, depression and alcohol dependenceHeilig, M. et al. | 2003
-
P.1.003 Lithium, but not valproate increases NAA concentrations in bipolar patients: An MRS studySilverstone, P. / Wu, R. H. / O'Donnell, T. / Ulrich, M. / Asghar, S. J. / Hanstock, C. C. et al. | 2003
-
P.1.024 Clinical application of low cholesterol as an indicator of suicidal risk in major depressionKim, Y. et al. | 2003
-
P.1.077 Long-term use of olanzapine/fluoxetine combination for major depressive disorder: A 76-week studyCorya, S. / Andersen, S. / Detke, H. / Van Campen, L. / Sanger, T. / Williamson, D. / Dube, S. et al. | 2003
-
P.1.130 The compounds Org 34517 and Org 34850 are potent antagonists of the glucocorticoid receptor both in vitro and in vivoThomson, F. / Craighead, M. W. / Watson, L. / Turnbull, Z. / McIntosh, L. / Speake, M. / Hillier, A. / Eason, S. / Shahid, M. / Marston, H. M. et al. | 2003
-
P.1.144 Amitriptiline mechanism of action may relate to oleate activated phospholipase D inhibitionKrzystanek, M. / Krupka-Matuszczyk, I. / Trzeciak, H. I. / Krzystanek, E. et al. | 2003
-
P.1.178 Association between the serotonin transporter linked polymorphic region gene (5-HTTLPR) and response to tricyclic antidepressants (TCAs)Tsapakis, E. M. / Checkley, S. / Kerwin, R. W. / Aitchison, K. J. et al. | 2003
-
P.1.180 Paroxetine improves sleep disturbances associated with major depressionDavidson, J. R. / Christie, J. / Duff, D. / Dube, E. et al. | 2003
-
P.1.228 Old vs. new antidepressants following ECTPapadimitriou, G. / Zervas, I. M. / Andreadaki, M. I. / Psarros, K. / Kontoangelos, K. / Dimitrakopoulos, C. / Vaidakis, N. / Papakostas, Y. et al. | 2003
-
P.1.226 Release of serotonin and serotonin receptors in the effects of antidepressantsPruus, K. / Rudissaar, R. / Vaarmann, A. / Allikmets, L. et al. | 2003
-
P.1.224 Transmembrane cell signalling influenced by fluoxetine and adenosine receptor agonist in C6 glioma- and natural killer (NK) cellsKovaru, H. / Fiserova, A. / Kovaru, F. / Malbohan, I. / Lisa, V. et al. | 2003
-
P.1.225 High- and low- affinity binding (affinity-modulation) of S-citalopram binding to the human 5-HT transporter. Importance of single amino acid substitutions in 20 positions of presumed importancePlenge, P. / Wiborg, O. et al. | 2003
-
P.1.235 Frequency of bipolar disorder spectrum in patients with first episode of depression and recurrent depressionLojko, D. / Suwalska, A. / Chlopocka-Wozniak, M. / Rybakowski, J. K. et al. | 2003
-
P.2.001 The effects of antipsychotic agents on sceletal muscle of psychiatric patients as it evidences by their serum creatine kinase activityReznik, I. / Kotler, M. / Shaked, G. / Weizman, A. / Spivak, B. / Meltzer, H. Y. et al. | 2003
-
P.2.060 Antidepressant-type effects of olanzapine in modified FST in ratsCobo-Realpe, B. L. / Rojas-Corrales, M. O. / Berrocoso, E. / Gibert-Rahola, J. / Mico, J. A. et al. | 2003
-
P.2.073 No seizure exacerbation from ziprasidone in youth with comorbid epilepsy and psychiatric disorders: A case seriesGonzalez-Heydrich, J. et al. | 2003
-
P.2.077 Neurological soft signs in first-episode schizophreniaCeskova, E. / Prikryl, R. / Kasparek, T. / Tronerova, E. et al. | 2003
-
P.2.082 Cognitive function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapineDeberdt, W. / De Deyn, P. P. / Carrasco, M. M. / Jeandel, C. / Hay, D. P. / Feldman, P. D. / Young, C. A. / Lehman, D. L. / Breier, A. et al. | 2003
-
P.2.139 Effectiveness of quetiapine up to 1600 mg/day: Short-term results with 14-month follow-upNagy, J. et al. | 2003
-
P.2.155 Treatment-induced changes in factor structure of schizophrenia after switching from typical to atypical antipsychoticsLecyk, A. / Loza, B. / Mazurek, I. et al. | 2003
-
P.3.017 A double-blind, randomized, placebo-controlled trial of quetiapine augmentation in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitorsDenys, D. / De Geus, F. / Van Megen, H. / Westenberg, H. G. et al. | 2003
-
P.3.026 Fixed doses of escitalopram and paroxetine for the treatment of social anxiety disorder (SAD)Lader, M. / Stender, K. / Burger, V. / Nil, R. et al. | 2003
-
P.3.052 Paroxetine improves the functional disability associated with mood and anxiety disordersSheehan, D. / Christie, J. / Dube, E. et al. | 2003
-
P.3.075 Duration of untreated illness in panic disorder: A poor outcome risk factor?Mundo, E. / Santini, A. / Salvadori, D. / Altamura, A. C. et al. | 2003
-
P.4.009 Cholinesterase inhibitors reduce the risk of institutionalization in patients with dementia in a naturalistic treatment settingLuong, D. / Sambrook, R. / Yu, A. et al. | 2003
-
P.4.017 Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's diseaseGrossberg, G. / Tariot, P. / Farlow, M. / Gergel, I. / Graham, S. / Jin, J. et al. | 2003
-
P.4.031 Cerebrovascular reactivity in dementia of Alzheimer's type assessed by acetazolamide SPECTChoi, Y. M. / Lee, D. W. et al. | 2003
-
P.4.042 Gene expression profiling of Alzheimer's lymphocytesKalman, J. / Zvara, A. / Kitajka, K. / Juhasz, A. / Pakaski, M. / Puskas, L. / Janka, Z. et al. | 2003
-
P.5.005 Lack of relationship between DRD2 and DAT polymorphisms and dopaminergic activity assessed by the apomorphine challengePinto, E. / Reggers, J. / Hansenne, M. / Pitchot, W. / Fuchs, S. / Gorwood, P. / Vaira, D. / Ansseau, M. et al. | 2003
-
P.5.015 Possible involvement of COX2 in the expression of morphine withdrawalFarina, R. / Milano, W. / Petrella, C. / Capasso, A. et al. | 2003
-
P.5.028 Estimates of illicit drug use during pregnancy by maternal interview and meconium analysisMortali, C. / Marchei, E. / Pellegrini, M. / Perez-Alarcon, E. / Puig, C. / Vall, O. / Pacifici, R. / Ordobas, L. / Pachini, S. / Garcia-Algar, O. et al. | 2003
-
P.5.031 Tryptophan hydroxylase polymorphism, family history, and severity of illness are associated with age of alcoholism onset in a Korean populationChung, I. W. / Kim, H. / Sribney, W. / Hong, J. B. / Lee, C. H. / Lee, K. Y. / Nan, H. M. / Kim, Y. S. / Manowitz, P. et al. | 2003
-
P.5.032 Involvement of 5-HT1 and 5-HT2 receptor in regulation of methamphetamine self-administration in ratsNovakova, J. et al. | 2003
-
P.6.022 5-HT2A receptor but not 5-HT transporter gene polymorphism is associated with harm avoidance in adolescents with anorexia nervosaRybakowski, F. / Dmitrzak-Weglarz, M. / Slopien, A. / Hauser, J. / Rajewski, A. et al. | 2003
-
P.6.028 Mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of ageRoose, S. P. / Holland, P. / Hassman, H. / Rosenthal, M. / Simmons, J. H. / Rodrigues, H. et al. | 2003
-
P.6.053 Effectiveness and safety of the once-daily OROS formulation of methylphenidate in adolescents with attention-deficit/hyperactivity disorderBiederman, J. et al. | 2003
-
P.6.071 Structural brain abnormalities in obsessive-compulsive disorder (OCD)Sobanski, T. / Wagner, G. / Gruhn, U. / Herwig, A. / Tauber, R. / Peikert, G. / Sauer, H. et al. | 2003
-
P.6.093 Effects of zalepon and zolpidem on driving ability: Evidence from on-the-road driving studies during normal trafficVolkerts, E. R. / Verster, J. C. et al. | 2003
-
Medications in development to treat stimulants addictionElkashef, A. / Vocci, F. et al. | 2003
-
Fluoxetine in the treatment of alcohol addicts with comorbid major depressionVukovic, O. / Pavlovic, Z. / Maric, N. / Jasovic-Gasic, M. et al. | 2003
-
S.03.03 Characterization and reconstitution of gamma-secretaseSteiner, H. / Edbauer, D. / Shirotani, K. / Haass, C. et al. | 2003
-
S.07.03 Gene expression and neuroleptic drug exposureFalkai, P. et al. | 2003
-
S.26.05 Environmental and genetic risk factors in schizophrenia on `cognitive and social function as endophenotypes'Davidson, M. / Weiser, M. / Reichenberg, A. / Rabinowitz, J. / Knobler, H. et al. | 2003
-
P.1.008 Lifetime prevalence of manic/hypomanic syndromes in young adultsBenazzi, F. et al. | 2003
-
P.1.014 The pharmacokinetics of fluoxetine in elderly volunteers ages 65-85Ferguson, J. / Hill, H. et al. | 2003
-
P.1.044 Amisulpride in combination with maprotiline in the treatment of psychotic depression - a clinical experienceJakovcevska-Kujundziska, M. / Filovska, V. / Lazarova, L. / Krsteska, R. et al. | 2003
-
P.1.079 Temporal profile of symptom improvement in antidepressant treatmentHirschfeld, R. / Burt, T. / Batzar, E. / Sackeim, H. et al. | 2003
-
P.1.081 Chronic treatment of various antidepressants increases Golf proteins in the rat nucleus accumbens and striatumTaoka, H. / Hamamura, T. / Endo, S. / Miki, M. / Lee, Y. / Miyata, S. / Ishihara, T. / Habara, T. / Oka, T. / Toma, K. et al. | 2003
-
P.1.134 Association study of a G-protein beta3 subunit gene polymorphism and major depressive disorders, symptomatology, and treatment responseLee, H. J. / Ryu, S. H. / Lee, M. S. et al. | 2003
-
P.1.132 First signs of improvement with tianeptine in the treatment of depression: An analysis of a double-blind study versus fluoxetineNovotny, V. / Faltus, F. et al. | 2003
-
P.1.171 Impairment in major depressive disorderPitchot, W. / Demyttenaere, K. / Albert, A. / Zhang, L. / De Cock, P. et al. | 2003
-
P.1.187 Chronic corticosterone attenuates 5-HT1A-mediated but not GABA-mediated inhibition of rat dorsal raphe neuronesIngram, C. D. / Gartside, S. E. / Leitch, M. M. / Fairchild, G. F. et al. | 2003
-
P.1.191 No clinically significant weight changes associated with long-term oxcarbazepine treatmentGrunze, H. / Severus, E. / Martenyi, F. / Sfikas, N. et al. | 2003
-
P.2.052 Addition of nicotine to the D2 antagonist raclopride or the weak D4 antagonist L-745,870 augments NMDA-induced currents in pyramidal cells from the rat medial prefrontal cortexMarcus, M. M. / Jardemark, K. E. / Konradsson, A. / Svensson, T. H. et al. | 2003
-
P.2.061 Long-acting risperidone injection improves and maintains quality of life in patients with schizophreniaMehnert, A. / Eerdekens, M. / Fleischhacker, W. W. et al. | 2003
-
P.2.101 The dosing pattern and clinical outcome of psychosis: A cluster analysis on 2078 cases with risperidone treatmentKim, C. Y. / Choi, S. K. / Lee, G. H. / Shin, Y. W. / Lee, C. et al. | 2003
-
P.2.111 Long-term effects of aripirazole on the negative symptoms of schizophreniaKostic, D. / Manos, G. / Stock, E. / Jody, D. / Archibald, D. / Tourkodimitris, S. / Marcus, R. et al. | 2003